



THOMSON REUTERS INTEGRITYSM

张慧

产品与方案解决专家，生命科学事业部

2014年11月



THOMSON REUTERS

为药物开发的不同阶段提供更多产品



METACORE (数据挖掘与分子通路分析) , METADRUG (系统药理学平台)

Thomson Reuters Integrity (化学、生物学、药理学数据库)

Cortellis for Clinical Trials Intelligence (临床试验情报数据库)

Cortellis for Regulatory Intelligence (药政法规情报数据库)

Cortellis for Competitive Intelligence (综合性竞争情报数据库)

Newport Premium
(全球仿制药/原料药/中间体的销售、研发和专利信息数据库)

Drug News (药物新闻)

Thomson Innovation (专利信息)



图书馆主页查看数据库登录链接

<http://lib.cpu.edu.cn/databases-index.htm>

收藏数据库网址：integrity.thomson-pharma.com

中国药科大学图书馆
CHINA PHARMACEUTICAL UNIVERSITY LIBRARY

中国药科大学图书馆 » 数字资源 » 试用数据库

中国药科大学图书馆 » 数字资源

类别

- 馆藏数据库
- 镜像数据库
- 试用数据库**
- 自建数据库

汤森路透Integrity数据库 (试用)

发布时间：2014-10-16 阅读次数：899

试用时间：从10月10日-10月31日，请大家积极试用。

请按照以下操作步骤登录使用 有任何问题

1. 点击网址：<http://integrity.thomson-pharma.com>
2. 请大家每次使用完该数据库后，一定点击

1、进入图书馆主页-数字资源-试用数据库

2、找到汤森路透Integrity数据库

3、按操作步骤登陆使用

4、收藏数据库网址

Integrity.thomson-pharma.com

The screenshot shows the homepage of the Integrity.thomson-pharma.com website. The header features the Thomson Reuters logo and the word "Integrity" in a large, bold font, with the tagline "Empowering knowledge-based drug discovery and development" to the right. Below the header, the page is divided into two main sections. On the left is a dark blue sidebar with a "Need Help?" button, a "WHAT'S NEW" section listing "LATEST RELEASE INFORMATION", "IMPORTANT NOTICES", and "MEETINGS AND REPORTS", and the Thomson Reuters logo at the bottom. The main content area on the right is white and contains a "Welcome" message. It has two sections: "Registered Users" with a login form (User Name, Password, and a Login button) and a "Forgotten login details?" link; and "First-time Users" with a "Self-Register" button highlighted by an orange box. A "Terms of Use" link is also present below the login form.

THOMSON REUTERS
IntegritySM
Empowering knowledge-based drug discovery and development

Need Help?
with login & registration

WHAT'S NEW

- LATEST RELEASE INFORMATION
- IMPORTANT NOTICES
- MEETINGS AND REPORTS

THOMSON REUTERS

Welcome

Registered Users

If you already have a User Name and Password to use Thomson Reuters Integrity, enter them here and click Login

User Name

Password

Login

Forgotten login details? Please [click here](#)

Use of this service is offered to Authorized Users on the condition that they accept the [Terms of Use](#)

First-time Users

If your company/institution has licensed Thomson Reuters Integrity under the self-registration mode, click here to register **Self-Register**

提纲

- Thomson Reuters Integrity数据库简介
- Integrity解决如下问题
 - 动态监测新分子实体和新靶标
 - 快速概览特定领域的研发进展和布局
 - 选题立项评估药物品种的综合状况
 - 比较药理学活性进行结构式优化
 - 一站式概览疾病综述和主流药物
 - 设置专属Email跟踪获取更新内容
- Q &A


提纲

- Thomson Reuters Integrity数据库简介
- Integrity解决如下问题
 - 动态监测新分子实体和新靶标
 - 快速概览特定领域的研发进展和布局
 - 选题立项评估药物品种的综合状况
 - 比较药理学活性进行结构式优化
 - 一站式概览疾病综述和主流药物
 - 设置专属Email跟踪获取更新内容
- Q &A


THOMSON REUTERS INTEGRITY

—整合的科学性信息

- Thomson Reuters Integrity专注于药物研发情报，包含441,800种具有药物活性的小分子和生物药，全面整合生物学、化学、药理学数据。



IC-50	2.80 nM
IC-50	8.60 nM



THOMSON REUTERS INTEGRITY

—整合的科学性信息

- 获取信息以支持决策，降低早期研发风险
- 服务于医药研发全过程的信息平台
- 为药物研发项目提供及时、准确的相关信息

特点：

- 事实型数据库
- 针对药物研发
- 每天更新
- 信息准确
- 专家意见
- 深度索引、高度关联

THOMSON REUTERS
Integrity[™]
Empowering knowledge-based drug discovery and development

Knowledge Areas Quick Search

Drugs & Biologics
Targets & Pathways
Genomics
Biomarkers
Organic Synthesis
Experimental Pharmacology
Pharmacokinetics/Metabolism
Clinical Studies
Disease Briefings
Companies & Research Institutions
Literature
Patents

Getting Started
Frequently Asked Questions
Learning Center

Quick Access to Key Drugs & Biologics Information
Drug Name Search [] Index [go]
Quick Access to Pipeline Information
Gateways to Development Status [] Condition Lookup []

Highlights March 29 - April 4, 2010

Today's News

Analgesic & Anesthetic Drugs
• CIPHER submits NDS to Health Canada for CIP-Tramadol ER for moderately severe pain

Cardiovascular Drugs
• Multaq approved and launched in U.K. by sanofi-aventis for management of atrial fibrillation

Metabolic Drugs
• EMA grants orphan drug designation to Protalix's taliglucerase alfa for Gaucher's disease

Oncolytic Drugs
• Adventix to discuss ANY-530 NDA for NSCLC with FDA
• EMA approves combination of Xeloda and oxaliplatin for adjuvant treatment of early colon cancer

Today's Featured Patents
Click here to display today's featured patent family entries in Integrity

Conferences

239th ACS National Meeting (March 21-25, San Francisco) 2010
CITATIONS

Diabetic Foot Global Conference (March 18-20, Los Angeles) 2010
CITATIONS

Conference of the International Society for Cellular Oncology (ISCO) (March 17-19, Dresden) 2010
CITATIONS

4th Biennial Conference of the International Society for Bipolar Disorders (March 17-20, Sao Paulo) 2010
CITATIONS REPORT

11th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCP) (March 17-20, Atlanta) 2010

WHAT'S NEW LATEST RELEASE INFORMATION

NEW INTEGRITY LEARNING CENTER

Weekly Insights
One-click access to recent and relevant information found in Integrity, updated each Monday.

The Starting Line
A selection of new molecular entities and targets ready to enter the R&D arena.

Pipeline on the Move
Milestones for drugs under active development.

Gateways to Gene-Related Studies
Studies delineating new areas of potential therapeutic intervention.

Gateways to Patents
The latest in intellectual property portfolios in drug R&D.

Gateways to Clinical Trials
Clinical studies cited in the most recent biomedical literature and at congresses.

Thomson Reuters Integrity 数据库主要内容

药物 (包括化药与生物药)	441,834(404,723化学结构式数据)
药物靶标以及发病通路图	2,564 药物靶标
药物/疾病相关的基因组学信息	34,325 相关基因
化学合成	26,851合成路线
药理/毒理试验数据	1,671,149药理/毒理
药代动力学/药物代谢试验数据	661,051药代/药动
疾病相关的综合性评述	149疾病综述
临床试验方案/结果	237,779临床试验
研发单位	15,134家企业或研发机构
文献期刊及会议	1,841,482个记录
专利文献	276,019个专利家族
实验模型	29,758实验模型

Thomson Reuters Integrity帮助您


• 监测国际最新研发动态

- 及时获取国际上的研发新闻
- 跟踪早期药物研发产品管线
- 了解药物开发全貌和 靶标、合成等最新进展

Reference	Preclinical Activity	Chemical/Pharmacological Activity	Target	Method	Parameter	Value	Source
1	Strain Sensitivity PK/Agonism	Cytotoxicity induction	Neurotoxin, rat	Dye assay	CC-25	0.120 nM	Ref. 1
2	Strain Sensitivity PK/Agonism	Hepatoblastoma	HEP22 human hepatoblastoma cells	Dye assay (MTS)	CC-50	0.180 nM	Ref. 2
3	Strain Sensitivity PK/Agonism	Cancer, Liver tumor/reduction	HPL human hepatoma cells	Dye assay (MTT)	CC-50	0.157 ± 0.008 nM	Ref. 3
4	Strain Sensitivity PK/Agonism	Tiglyridase	3T3-L1 mouse adipocytes	EC-50	0.105 µM		Ref. 4
5	Strain Sensitivity PK/Agonism	Prostaglandin synthase activation, in vitro	Cyclo-oxygenase	Cyclo-oxygenase assay	EC-40	10 µM	Ref. 5
6	Strain Sensitivity PK/Agonism	Prostaglandin synthase activation, in vitro	Prostaglandin synthase	Prostaglandin synthase assay	EC-50	1.30 nM	Ref. 6

• 药理学实验数据比较

- 寻找具有某药理学特性的相关药物
- 比较同一领域/类似结构等药物之间的药理学活性



• 靶标进展报告和通路图

- 了解某一靶标的研发进展、研究领域、作用机理等
- 促进药物设计及基础机理的研究

• 疾病综述

- 了解疾病信息、靶标、目前上市药物/治疗方法等
- 申请基金或课题时作为课题背景信息来源

Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs

Diabetes

- [Facts about Diabetes](#)
- [Diagnosis](#)
- [Prevention](#)
- [Treatment](#)
- [Targets for Therapeutic Intervention](#)
- [Latest Headlines](#)
- [Glossary of Terms](#)

提纲

- Thomson Reuters Integrity数据库简介
- Integrity解决如下问题
 - 动态监测新分子实体和新靶标
 - 快速概览特定领域的研发进展和布局
 - 选题立项评估药物品种的综合状况
 - 比较药理学活性进行结构式优化
 - 一站式概览疾病综述和主流药物
 - 设置专属Email跟踪获取更新内容
- Q &A

- Drugs & Biologics
- Targets & Pathways
- Genomics
- Biomarkers
- Organic Synthesis
- Experimental Pharmacology
- Experimental Models
- Pharmacokinetics/Metabolism
- Clinical Studies
- Disease Briefings
- Companies & Research Institutions
- Literature
- Patents

Quick Access to Key Drugs & Biologics Information

Drug Name Search

Index

GO

Quick Access to Pipeline Information

Gateways to
Development Status

Condition Lookup

Highlights

January 6 - 12, 2014

Today's News

Eye Disorders

- RegeneRx receives orphan drug designation for thymosin beta4

Diagnostics

- RadioMedix receives orphan drug designation for GalioMedix

Endocrine Disorders

- FDA grants orphan drug status to DiaVacs' immunotherapy product for type 1 diabetes
- FDA accepts for filing A/Eterna Zentaris' NDA for macimorelin acetate for AGHD
- NPS Pharmaceuticals receives European orphan drug designation for Natpara

Cancer

- FDA grants fast track designation to Peregrine's immunotherapy bavituximab for second-line NSCLC

Today's Features

Click here to display in Integrity

Conferences

52nd Annual Meeting (ACNP) (December 1-6, 2013)
[CITATIONS](#)

HEP DART (December 8-12, Kohala Coast, Hawaii) 2013
[CITATIONS](#)

Annual Meeting of the American Society of Hematology (December 7-10, New Orleans) 2013
[CITATIONS](#)

Winter Meeting of the British Thoracic Society (December 4-6, London) 2013
[CITATIONS](#)

18th International Symposium on Cancer Chemotherapy, JFCR-ISCC (December 4-5, Tokyo) 2013
[CITATIONS](#)

99th Annual Meeting of the Radiological Society of North America (RSNA) (December 1-6, Chicago) 2013
[CITATIONS](#)

Getting Started

- Frequently Asked Questions
 - English
 - Japanese
 - Biomarkers - English
 - Biomarkers - Japanese
- Learning Center
 - Live Training
 - Recorded Training
 - Quick Guides

常见问题、检索实例、视频教程和快速指南

WHAT'S NEW

- LATEST RELEASE INFORMATION
- IMPORTANT NOTICES
- MEETINGS AND REPORTS

NEW INTEGRITY LEARNING CENTER

Weekly Insights

One-click access to recent and relevant information found in Integrity, updated each Monday.

The Starting Line

A selection of new molecular entities and targets ready to enter the R&D arena.

Pipeline on the Move

Milestones for drugs under active development.

Gateways to Gene-Related Studies

Studies delineating new areas of potential therapeutic intervention.

Gateways to Patents

The latest in intellectual property portfolios in drug R&D.

Gateways to Clinical Trials

Clinical studies cited in the most recent biomedical literature and at congresses.

- Drugs & Biologics
- Targets & Pathways
- Genomics
- Biomarkers
- Organic Synthesis
- Experimental Pharmacology
- Experimental Models
- Pharmacokinetics/Metabolism
- Clinical Studies
- Disease Briefings
- Companies & Research Institutions
- Literature
- Patents

Getting Started

- ▶ Frequently Asked Questions
- ▶ English
- ▶ Japanese
- ▶ Biomarkers - English
- ▶ Biomarkers - Japanese
- ▶ Learning Center
- ▶ Live Training
- ▶ Recorded Training
- ▶ Quick Guides

Quick Access to Key Drugs & Biologics Information

Drug Name Search

GO

Index

Quick Access to Pipeline Information

Gateways to
Development Status

Condition Lookup

Highlights

January 6 - 12, 2014

Today's News

- **Eye Disorders**
- RegeneRx receives orphan drug designation for thymosin beta4
- **Diagnostics**
- RadioMedix receives orphan drug designation for GalioMedix
- **Endocrine Disorders**
- FDA grants orphan drug status to DiaVacs' immunotherapy product for 1 diabetes
- FDA accepts for filing Aeterna Zentaris' NDA for macimorelin acetate for AGHD
- NPS Pharmaceuticals receives European orphan drug designation for Natpara
- **Cancer**
- FDA grants fast track designation to Peregrine's immunotherapy bavituximab for second-line NSCLC

Today's Featured Patents

Click here to display today's featured patent family entries in Integrity

Conferences

- 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP) (December 8-12, Hollywood) 2013
[CITATIONS](#)
- HEP DART (December 8-12, Kohala Coast, Hawaii) 2013
[CITATIONS](#)
- Annual Meeting of the American Society of Hematology (December 7-10, New Orleans) 2013
[CITATIONS](#)
- Winter Meeting of the British Thoracic Society (December 2013)
[CITATIONS](#)
- 18th International Symposium on Cancer Chemotherapy (December 4-5, Tokyo) 2013
[CITATIONS](#)
- 99th Annual Meeting of the Radiological Society of North America (RSNA) (December 1-6, Chicago) 2013
[CITATIONS](#)

快讯区

当天新发生的新闻

当天新发布的重要专利

行业会议发布的最新信息

WHAT'S NEW

- LATEST RELEASE INFORMATION
- IMPORTANT NOTICES
- MEETINGS AND REPORTS

NEW INTEGRITY LEARNING CENTER

Weekly Insights

One-click access to recent and relevant information found in Integrity, updated each Monday.

The Starting Line

A selection of new molecular entities and targets ready to enter the R&D arena.

Pipeline on the Move

Milestones for drugs under active development.

Gateways to Gene-Related Studies

Studies delineating new areas of potential therapeutic intervention.

Gateways to Patents

The latest in intellectual property portfolios in drug R&D.

Gateways to Clinical Trials

Clinical studies cited in the most recent biomedical literature and at congresses.

Highlights

January 8 - 12, 2014

Today's News

雷根内克斯的胸腺肽beta 4
收到孤儿药物认定

Eye Disorders

- RegeneRx receives orphan drug designation for thymosin beta4

Diagnostics

- RadioMedix receives orphan drug designation for GalioMedix

Endocrine Disorders

- FDA grants orphan drug status to DiaVacs' immunotherapy product for type 1 diabetes
- FDA accepts for filing Aeterna Zentaris' NDA for macimorelin acetate for AGHD
- NPS Pharmaceuticals receives European orphan drug designation for Natpara

FDA授予Bavituximab二线治疗非小细胞肺癌快速审批通道

Cancer

- FDA grants fast track designation to Peregrine's immunotherapy bavituximab for second-line NSCLC

新闻周刊：本周视点

- Drugs & Biologics
- Targets & Pathways
- Genomics
- Biomarkers
- Organic Synthesis
- Experimental Pharmacology
- Experimental Models
- Pharmacokinetics/Metabolism
- Clinical Studies
- Disease Briefings
- Companies & Research Institutions
- Literature
- Patents

Getting Started

- ▶ Frequently Asked Questions
- ▶ English
- ▶ Japanese
- ▶ Biomarkers - English
- ▶ Biomarkers - Japanese
- ▶ Learning Center
- ▶ Live Training
- ▶ Recorded Training
- ▶ Quick Guides

Quick Access to Key Drugs & Biologics Information

Drug Name Search

Index

GO

Quick Access to Pipeline Information

Gateways to
Development Status

Condition Lookup

Highlights

January 6 - 12, 2014

Today's News

Eye Disorder

• RegeneR

Diagnostic

• RadioMe

Endocrine

• FDA gran

1 diabete

• FDA acc

AGHD

• NPS Pha

Natpara

Cancer

• FDA gran

for secon

一周新出现的具有治疗作用的新化合物或靶标

一周出现的重要的研发状态改变事件

一周具有潜在治疗前景基因相关研究

Today's Patents

Click here to display today's featured patent family entries in Integrity

Conferences

52nd Ann

(ACNP) (D

CITATIONS

HEP DART

(December 8-12, Kohala Coast, Hawaii) 2013

CITATIONS

Annual Me

New Orlea

CITATIONS

Winter Me

2013

CITATIONS

18th International Symposium on Cancer Chemotherapy, JFCR- ISCC (December 4-5, Tokyo) 2013

CITATIONS

99th Annual Meeting of the Radiological Society of North America (RSNA) (December 1-6, Chicago) 2013

CITATIONS

一周新发布的专利情况

一周在生物学医学论文与会议中被引用的临床试验研究

WHAT'S NEW

- LATEST RELEASE INFORMATION
- IMPORTANT NOTICES
- NEWS REPORTS

本周视点

Weekly Insights

One-click access to recent and relevant information found in Integrity, updated each Monday.

The Starting Line

A selection of new molecular entities and targets ready to enter the R&D arena.

Pipeline on the Move

Milestones for drugs under active development.

Gateways to Gene-Related Studies

Studies delineating new areas of potential therapeutic intervention.

Gateways to Patents

The latest in intellectual property portfolios in drug R&D.

Gateways to Clinical Trials

Clinical studies cited in the most recent biomedical literature and at congresses.

加速发现：最近新公布的具有活性的新分子实体



THOMSON REUTERS
IntegritySM

Empowering knowledge-based drug discovery and development

Knowledge Areas

Quick Search



Exit

Support/Help

Query Manager / Alert Center

Reports

Drugs & Biologics

Targets & Pathways

Quick Access to Key Drugs & Biologics Information

The Starting Line - Mozilla Firefox

integrity.thomson-pharma.com/integrity/xmlxsl/starting_line_pkg.startingLine

The Starting Line

THOMSON REUTERS

The Starting Line
January 06 - 12, 2014

Company	Product	Condition	Comments
Amgen	AMG-3969	Diabetes type 2	Glucose Lowering Agents
Korea Research Institute Chem Technol Korea University	KR-67105	Diabetes type 2 Metabolic syndrome	11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
University North Carolina, Chapel Hill	UNC-2250 UNC-2250B	Cancer	Mer Receptor Inhibitors Signal Transduction Modulators

Source: Thomson Reuters IntegritySM
Copyright 2014 Prous Science. All rights reserved.

Print Full Table

1

- Live Training
- Recorded Training
- Quick Guides

HEP DART (December 8-12, Kohala Coast, Hawaii) 2013

[CITATIONS](#)

Annual Meeting of the American Society of Hematology (December 7-10, New Orleans) 2013

[CITATIONS](#)

Winter Meeting of the British Thoracic Society (December 4-6, London) 2013

[CITATIONS](#)

18th International Symposium on Cancer Chemotherapy, JFCR-ISCC (December 4-5, Tokyo) 2013

[CITATIONS](#)

99th Annual Meeting of the Radiological Society of North America (RSNA) (December 1-6, Chicago) 2013

[CITATIONS](#)

WHAT'S NEW

- LATEST RELEASE INFORMATION
- IMPORTANT NOTICES
- MEETINGS AND REPORTS

NEW INTEGRITY
LEARNING CENTER

Weekly Insights

One-click access to recent and relevant information found in Integrity, updated each Monday.

The Starting Line

A selection of new molecular entities and targets ready to enter the R&D arena.

Pipeline on the Move

Milestones for drugs under active development.

Gateways to Gene-Related Studies

Studies delineating new areas of potential therapeutic intervention.

Gateways to Patents

The latest in intellectual property portfolios in drug R&D.

Gateways to Clinical Trials

Clinical studies cited in the most recent biomedical literature and at congresses.



THOMSON REUTERS

紧密跟踪：汇总药物研发阶段的改变



THOMSON REUTERS
IntegritySM

Empowering knowledge-based drug discovery and development

Records Retrieved

7 in Pipeline on the Move

Options

Pipeline on the Move (December 30 - 5, 2014)

[< Previous](#)

Organization	Main Name	Condition	Milestone	Country/Area	Notes
Heat Biologics	HS-410	Cancer, bladder	Phase I/II	United States	Treatment of patients with high-risk non-muscle invasive bladder cancer who have undergone transurethral resection of bladder tumor and received prior treatment with BCG; Injections; Parenteral
NPS Pharmaceuticals	Teduglutide	Short-bowel syndrome	Phase III	United States	Treatment of short-bowel syndrome in pediatric patients aged 1 year through 17 years, who are dependent on parenteral support; Subcutaneous
Cell Therapeutics	Tosedostat	Hematologic/blood cancer	On Hold lifted	United States	Partial Clinical Hold lifted in US by Cell Therapeutics for the treatment of hematologic/blood cancer
Peregrine Pharmaceuticals	Bavituximab	Cancer, lung (non-small cell) (NSCLC)	Phase III		In combination with docetaxel in patients with second line stage IIIb/IV non-squamous non-small-cell lung cancer; Infusion; Intravenous
Serodus Evolve	EV-077	Nephropathy, diabetic	Licensed		Licensed to Serodus by Evolve for the treatment of diabetic nephropathy
Genzyme	Alemtuzumab	Multiple sclerosis, relapsing-remitting	Complete Response Letter	United States	Infusion; Intravenous
Veloxis Pharmaceuticals	Tacrolimus	Transplant rejection, kidney	NDA Filed	United States	Prevention of transplant rejection in kidney transplant patients; Tablets, once-daily; Using MeltDose technology

99th Annual Meeting of the Radiological Society of North America (RSNA)
(December 1-6, Chicago) 2013

[CITATIONS](#)

追踪最新收录的靶标

Knowledge Areas

Quick Search



Support/Help

Query Manager/Alert Center

Reports

Drugs & Biologics

Targets & Pathways

Genomics

Biomarkers

Organic Synthesis

Experimental Pharmacology

Experimental Models

Pharmacokinetics/Metabolism

Clinical Studies

Disease Briefings

Companies & Research Institutions

Literature

Patents

Getting Started

Frequently Asked Questions

English

Japanese

Biomarkers - English

Biomarkers - Japanese

Learning Center

Live Training

Recorded Training

Quick Guides

进入检索中心-靶标检索

Quick

Drug Name Search

Index

go

Quick Access to Pipeline Information

Gateways to
Development Status

Condition Lookup

Highlights

November 11 - 17, 2013

Today's News

Metabolic Disorders

- Patisiran receives FDA fast track designation for TTR-mediated amyloidosis

Infections

- Affinium obtains QIDP designation for AFN-1252, completes dosing in study of new prodrug
- FDA grants QIDP designation to oritavancin
- Preclinical antiviral efficacy seen in Tekmira's TKM-Ebola and TKM-Marburg programs

Respiratory Disorders

- Boehringer Ingelheim seeks European approval of tiotropium Respimat for asthma

Today's Featured Patents

Click here to display today's featured patent family entries in Integrity

Conferences

Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS) (November 10-14, San Antonio, TX) 2013

[CITATIONS](#)

43rd Annual Meeting of the Society for Neuroscience (November 9-13, San Diego) 2013

[CITATIONS](#)

28th Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 8-10, National Harbor) 2013

[CITATIONS](#)

ASCO-EORTC-NCI Annual Meeting on Markers in Cancer (November 7-9, Brussels) 2013

[CITATIONS](#)

Annual Meeting of the American Association for the Study of Liver Diseases (November 1-5, Washington, D.C.) 2013

[CITATIONS](#)

64th AALAS National Meeting (October 27-31, Baltimore) 2013

WHAT'S NEW

- LATEST RELEASE INFORMATION
- IMPORTANT NOTICES
- MEETINGS AND REPORTS

NEW INTEGRITY LEARNING CENTER

Weekly Insights

One-click access to recent and relevant information found in Integrity, updated each Monday.

The Starting Line

A selection of new molecular entities and targets ready to enter the R&D arena.

Pipeline on the Move

Milestones for drugs under active development.

Gateways to Gene-Related Studies

Studies delineating new areas of potential therapeutic intervention.

Gateways to Patents

The latest in intellectual property portfolios in drug R&D.

Gateways to Clinical Trials

Clinical studies cited in the most recent biomedical literature and at congresses.



查看最新收录或更新的靶标报告

THOMSON REUTERS
IntegritySM

Targets & Pathways

Knowledge Areas Quick Search go Home Support/Help Query Manager / Alert Center Reports

2225 Records in Targets & Pathways

Advanced Search Session History Clear Form **Start**

Targets & Pathways

Targetscapes

Click a condition to view molecular landscapes related to the selected condition.

- AIDS
- Cancer
- Cardiovascular Disorders
- Congenital defects
- Critical care medicine
- Dermatological Disorders
- Disorders of Sexual Function, Breast and Reproduction
- Endocrine Disorders
- Eye Disorders
- Gastrointestinal Disorders
- Genetic Disorders
- Genitourinary Disorders
- Hematologic Diseases
- Immunological Disorders
- Infections
- Metabolic Diseases
- Musculoskeletal and Connective Tissue Disorders
- Neurological Disorders
- Other disorders (Systemic disorders)
- Pain
- Poisoning

Select Value

Classification

Target Name

Description

GenBank ID

Entrez Gene ID

PDB ID

UniProtKB

KEGG ID

EC Classification

Condition

Targetscape (Y/N)

Scientific Animations (Y/N)

Scientific Animations Title

Last Updated

Available Since

Select Value

Optional Value

Optional Value

om 20130401

Index AND

Index AND

Index AND

Active Development

Index AND

关联药物数量较少的的则为目前研究不多的较新靶标

Records Retrieved Records 1 to 25 of 141 retrieved

Options

1 2 3 4 5 6

Targets & Pathways Search Results

Query > Available Since = from 20130401

Target Name	Type	Major Condition & Status	Links
<input type="checkbox"/> Acylglycerol kinase, mitochondrial precursor	Protein	Major Condition Cancer	V C E UniProtKB: Q53H12
<input type="checkbox"/> Adrenomedullin	Protein	Major Condition Critical care medicine Renal Disorders	V C E UniProtKB: P35318

Records Retrieved 1 Record retrieved

Options

Targets & Pathways Search Results

CDK2/Cyclin E

Type	Protein
Related Names	CCNE; CCNE1; CDK2 variant 1; Cyclin E1; Cyclin-dependent kinase 2, transcript variant 1; p33(CDK2)
Description/Function	CDK2/Cyclin E is a complex that mediates cell cycle progression. The enzymes are also involved in regulation of transcription. CDK1 is activated by association with cyclin E which results in formation of a cyclin-dependent kinase complex. Inhibition of CDKs selectively interrupts the cell cycle in cancer cells.
Scientific Animations	 Cell Cycle: Schematic Diagram  Retinoblastoma: Role in G1 Phase Progression
Condition (Status)	<input type="checkbox"/> Collapse All <input checked="" type="checkbox"/> Expand All V 1 Conditions <input checked="" type="checkbox"/> Cancer E (View Drugs) C 0 Conditions E 1 Conditions
Related Mechanisms	CDK2/Cyclin E Inhibitors
Products Under Development and Launched	▼ Cancer

Related Information

Drugs & Biologics 198	Biomarkers 11	Targets & Pathways 3	Genomics 2	Experimental Pharmacology 597
-----------------------	---------------	----------------------	------------	-------------------------------

提纲

- Thomson Reuters Integrity数据库简介
- Integrity解决如下问题
 - 动态监测新分子实体和新靶标
 - 快速概览特定领域的研发进展和布局
 - 选题立项评估药物品种的综合状况
 - 比较药理学活性进行结构式优化
 - 一站式概览疾病综述和主流药物
 - 设置专属Email跟踪获取更新内容
- Q &A

快速概览特定领域的研发进展和布局

- 肝癌领域的当前在研药物研发进展和布局
- 结构式检索举例

431个肝癌相关的药物记录

Records Retrieved

431 in Drugs & Biologics Search Results

Options

Drugs & Biologics Search Results

1 2 3 4 5 6 7 8 9 10 [Next>] [Last>>]

Query > Condition = "Cancer, liver"

Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Product Category	Therapeutic Group	Mechanism of Action	Organization
70011*	Launched-1956	MMc	Mitomycin (USAN) Mitomycin C (JAN)	Ametycine Mito-medac Mitosol Mutamycin		Antibiotics Lung Cancer Therapy Oncolytic Drugs Bladder Cancer Therapy Digestive/Gastrointestinal Cancer Therapy Colorectal Cancer Therapy Liver Cancer Therapy	DNA Alkylating Drugs Apoptosis Inducers	EORTC National Cancer Institute Bristol-Myers Squibb (Originator) Mobius Therapeutics Medac Ohio State University Sanofi Medical Research Council Halozyme
90434*	Phase III	E-5166 K-333 NIK-333 NK-333	Acyclic retinoid Peretinoin (Prop INN) Polyprenoic acid		Retinoids	Chemopreventive Agents Oncolytic Drugs	Retinoid RARbeta Ligands Retinoid RXRalpha Ligands Apoptosis Inducers	Kowa Pharmaceutical Eisai (Originator)
90725*	Launched-1995	NSC-296961 SAPEP WR-2721 YM-08310	Amifostine hydrate (BANM; Rec INN); (USAN) Gammaphos Ethiofos (former USAN)	Ethiol		Myelodysplastic Syndrome Therapy Treatment of Mucositis Radioprotectants/Radiomitigators Chemoprotective Agents Cancer Associated Disorders, Treatment of		National Cancer Institute Pinnacle Pharmaceuticals MedImmune Oncology (Originator)

Filter by Statistics

- ▶ Development Status
- ▶ Organization
- ▶ Major Therapeutic Groups
- ▶ Therapeutic Group
- ▶ Major Condition Groups
- ▶ Condition
 - ▶ Mechanistic Scope
 - Molecular Mechanisms
 - Cellular Mechanisms
- ▶ Major Product Categories
- ▶ Product Category
- ▶ Launch Year
- ▶ Target
- ▶ Under Active Development / No Development Reported
- ▶ Filter Only Lead Compounds
- ▶ Natural Source Categories
- ▶ Natural Source Scientific Name
- ▶ Prescription/ Indication Type
- ▶ Administration Route

概览药物的研发状态：Filter by Statistics

Records Retrieved

431 in Drugs & Biologics Search Results

Options

Drugs & Biologics Search Results

1 2 3 4 5 6 7 8 9 10 [Next>] [Last>>]

Query > Condition = "Cancer, liver"

Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Mechanism of Action	Organization
<input type="checkbox"/> 070011	Launched-1956	MMc	Mitomycin (USAN) Mitomycin C (JAN)	Antitumor Mitomycin Mucositis	Alkylating Apoptosis Inducers	NCI National Cancer Institute Bristol-Myers Squibb (Originator) Mobius Therapeutics Medac Ohio State University Sanofi Medical Research Council Halozyme
<input type="checkbox"/> 090434	Phase III	E-5166 K-333 NIK-333 NK-333	Acyclic retinoid Peretinoin (Prop INN) Polyprenoic acid		Retinoids	Chemopreventive Agents Oncolytic Drugs Retinoid RARbeta Ligands Retinoid RXRalpha Ligands Apoptosis Inducers
<input type="checkbox"/> 090725	Launched-1995	NSC-296961 SAPEP WR-2721 YM-08310	Amifostine hydrate (BANM; Rec INN); USAN) Gammaphos Ethiofos (former USAN)	Ethiol		Myelodysplastic Syndrome Therapy Treatment of Mucositis Radioprotectants/Radiomitigators Chemoprotective Agents Cancer Associated Disorders, Treatment of

检索结果进行分析：药物技术类型；药物来源；治疗领域；作用机制；研发机构；研发阶段；药物靶标；给药途径等等

Filter by Statistics

- ▶ Development Status
- ▶ Organization
- ▶ Major Therapeutic Groups
- ▶ Therapeutic Group
- ▶ Major Condition Groups
- ▶ Condition
- ▶ Mechanistic Scope
 - Molecular Mechanisms
 - Cellular Mechanisms
- ▶ Major Product Categories
- ▶ Product Category
- ▶ Launch Year
- ▶ Target
- ▶ Under Active Development / No Development Reported
- ▶ Filter Only Lead Compounds
- ▶ Natural Source Categories
- ▶ Natural Source Scientific Name
- ▶ Prescription/ Indication Type
- ▶ Administration Route

研发阶段分析：概览领域内最新进展

可进一步过滤感兴趣的内容




Export to Excel



Snapshot Tool

Development Status

Condition = "Cancer, liver"



Display Options

Horizontal Display Vertical Display Pie Chart Display

View Subset(s)

Print Chart

Records Retrieved 112 in Drugs & Biologics Search Results

Options

Drugs & Biologics Search Results

1 2 3 4 5 6 7 8 9 10 [Next>] [Last>>]


Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Product Category	Therapeutic Group	Mechanism of Action	Organization
<input type="checkbox"/> 090434	Phase III	E-5166 K-333 NIK-333 NK-333	Acyclic retinoid Peretinoin (Prop INN) Polyprenoic acid		Retinoids	Chemopreventive Agents Oncolytic Drugs	Retinoid RARbeta Ligands Retinoid RXRalpha Ligands Apoptosis Inducers	Kowa Pharmaceutical Eisai (Originator)
<input type="checkbox"/> 103954	Phase II	CB-1954	Tretazicar (Rec INN)		Radiosensitizers	Liver Cancer Therapy	DNA-Damaging Drugs	Cancer Research UK Morvus Technology Institute of Cancer Research (ICR) (Originator) etc.

靶标分析：431个药物对应222个靶标

概览本领域热门和悄然兴起的靶标

Target

Condition = "Cancer, liver"




药物类别分析：洞悉热门和新兴技术及各类药物目前的状态

寡核苷酸，多肽，基因治疗，反义治疗，癌症疫苗，溶瘤病毒，重组蛋白，人源化单克隆抗体，siRNAs，基因定向酶前药治疗等

Product Category

Condition = "Cancer, liver"




研究机构分析：了解同行和竞争者的目前状态

美国国家癌症研究所，安德森癌症研究中心，法伯癌症研究所，南京大学，梅约医学中心，辉瑞，百时美施贵宝，中科院等

Organization

Condition = "Cancer, liver"




天然产物药物来源分析：

植物类；动物类；海藻类；细菌类；真菌类药物

Natural Source Categories

Condition = "Cancer, liver"




药物的天然产物来源名称分析：

甘草、黄芩、柴胡、薏苡、芍药、人参、半夏，金丝小枣等

Natural Source Scientific Name

.. Condition = "Cancer, liver"



以Erlotinib为例查看药物报告

Records Retrieved 1 in Drugs & Biologics Options

Drug Metabolites - Mozilla Firefox

integrity.thomson-pharma.com/integrity/xmlsl/PK_MET_LIST.met_popup?p_entry_number=250837&p_a

Thomson Reuters Integrity
Copyright 2013 - Prous Science. All rights reserved.
<http://integrity.thomson-pharma.com>

Metabolism

The diagram illustrates the metabolic pathways of Erlotinib. The parent compound, Erlotinib (O SI-356, CP-394356), is shown at the center. It features a quinazoline core with two methoxypropoxy groups at the 6 and 7 positions and a 4-acetylphenylamino group at the 2 position. The diagram shows several metabolic transformations:

- M9:** Sulfation of the acetyl group to a sulfonic acid ($\text{O SO}_3\text{H}$).
- M17:** Hydroxylation of the acetyl group to a hydroxyacetyl group (OH).
- M3:** Glucuronidation of the acetyl group (O - Gluc).
- M10:** Glucuronidation of one of the methoxypropoxy groups (Gluc - O).
- M7:** Hydroxylation of the phenyl ring of the acetyl group to a hydroxyacetyl group (OH).
- M16:** Hydroxylation of the phenyl ring of the acetyl group to a hydroxyacetyl group (OH).
- M12:** Hydroxylation of the phenyl ring of the acetyl group to a hydroxyacetyl group (OH).

Chemical structures are shown with arrows indicating the metabolic transformations from the parent compound to the metabolites.

以Erlotinib为例查看药物报告，销售额数据

Records Retrieved 1 in Drugs & Biologics Options

Product Sales Results - Mozilla Firefox

integrity.thomson-pharma.com/integrity/xmlxsl/pk_com_list.showProductSalesResults?p_entryNumber=250837

Thomson Reuters Integrity
Copyright 2013 - Prous Science. All rights reserved.
http://integrity.thomson-pharma.com

Astellas Pharma (www.astellas.com)

Brand Name	Drug Name		Conditions			
Tarceva	Erlotinib hydrochloride		Cancer, lung (non-small cell) (NSCLC)			
Geographic Area	Year	Q1 (M)	Q2 (M)	Q3 (M)	Q4 (M)	Annual Sales (M)
Worldwide	2012	JPY 8000	JPY 8600	JPY 8700	JPY 8400	JPY 33700 (USD 427)
Worldwide	2013	JPY 9100	JPY 8300	JPY 8900		

Fiscal Year Ends: Mar 31

Roche (www.roche.com)

Brand Name	Drug Name		Conditions			
Tarceva	Erlotinib hydrochloride		Cancer, pancreas Cancer, lung (non-small cell) (NSCLC) Cancer, pancreas metastatic			
Geographic Area	Year	Q1 (M)	Q2 (M)	Q3 (M)	Q4 (M)	Annual Sales (M)
Japan	2007				CHF 2	CHF 2 (USD 2)
Japan	2008	CHF 8	CHF 12	CHF 11	CHF 16	CHF 47 (USD 44)
Japan	2009	CHF 15	CHF 17	CHF 16	CHF 19	CHF 67 (USD 62)



易于打印的药物综述报告

Molecular Mechanism	Cellular Mechanism	
EGFR (HER1; erbB1) Inhibitors	Inhibitors of Signal Transduction Pathways	
Product Category	Therapeutic Group	Prescription/ Indication Type
Tyrosinase Inhibitors	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors	Oral

.....

Tyrosinase Inhibitors

.....

- Organization**
- [National Cancer Institute](#)
 - [Genentech](#)
 - [EORTC](#)
 - [Roche](#)
 - [Astellas Pharma](#)
 - [Pfizer \(Originator\)](#)
 - [Chugai Pharmaceutical](#)
 - [M.D. Anderson Cancer Center](#)
 - [University of California, San Francisco](#)
 - [Sanofi](#)
 - [Astellas Pharma](#)
 - [Schwarz Pharma](#)
 - [National Cancer Research Institute](#)
 - [Mayo Clinic](#)
 - [Dana-Farber Cancer Institute](#)
 - [University of California, Davis](#)
 - [Canadian Cancer Society Research Inst](#)

Product Summary

Erlotinib hydrochloride is an EGFR (erbB) the oral treatment of locally advanced o

Product Summary Details - Mozilla Firefox

integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.productSummaryDetails?p_entryNumber=250837

Phase I/II	National Cancer Institute (NCI)	Oligodendroglioma
Phase I	National Cancer Institute (NCI)	Barrett's esophagus
Phase I	Mayo Clinic	Cholangitis, sclerosing

Development Status - Launched, Registered or Under Active Development

Country/Area	Phase	Organization	Brand Name	Condition	Indication	Admin. Route	Formulation
	Phase III	Genentech		Cancer, pancreas metastatic	First-line treatment in combination with bevacizumab		
Canada	Registered - 2005	Astellas Pharma	Tarceva	Cancer, lung (non-small cell) (NSCLC)	In patients with advanced or metastatic disease following failure of first or second-line chemotherapy	oral	Tablets
Europe	Phase III	Roche		Cancer, lung (non-small cell) (NSCLC)	Adjuvant treatment; in first-line treatment in combination with Avastin; as first-line maintenance therapy for unresectable NSCLC		
European Union	Registered - 2005	Roche	Tarceva	Cancer, lung (non-small cell) (NSCLC)	Stage IIIB/IV disease after failure of at least one prior chemotherapy regimen	oral	Tablets, once-daily
European Union	Registered - 2007	Roche	Tarceva	Cancer, pancreas metastatic	First line treatment of advanced pancreatic cancer, in combination with gemcitabine	oral	Tablets, once-daily
European Union	Registered - 2010	Roche	Tarceva	Cancer, lung (non-small cell) (NSCLC)	First-line maintenance treatment after platinum-based first-line chemotherapy in patients with advanced non-small cell lung cancer	oral	Tablets, once-daily



THOMSON
汤森路透

更多药物相关的详尽信息，点击即可获取

Phase 1 **Records Retrieved** 784 in Experimental Pharmacology **Options**

Phase 1 **Experimental Pharmacology Search Results** 1 2 3 4 5 6 7 8 9 10 (Next>) (Last>>)

Phase 1	Drug Name	Biomarker	Mechanism of Action	Experimental Activity	Pharmacological Activity	Material / Experimental Model	Method	Parameter	Value	Details
Phase 1	<input type="checkbox"/> Erlotinib			Cancer, vulvar (squamous cell) remission/reduction, IN VITRO	Cytotoxicity @ 72 h	A431 human vulvar epidermoid carcinoma cells (EGFR-overexpressing)	Dye assay (XTT)	CC-50	1.27 µM	Pat. 1
Phase 1	<input type="checkbox"/> Erlotinib			Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO	Cytotoxicity @ 72 h	NCI-H1975 human non-small-cell lung cancer cells	Dye assay (XTT)	CC-50	3.99 µM	Pat. 1
Phase 1	<input type="checkbox"/> Erlotinib			Cancer, ovary (adenocarcinoma) remission/reduction, IN VITRO	Cytotoxicity @ 72 h	SKOV3 human ovary adenocarcinoma cells	Dye assay (XTT)	CC-50	> 10 µM	Pat. 1
Phase 1	<input type="checkbox"/> Erlotinib			EGFR (erbB1) inhibition, IN VITRO	Protein-tyrosine kinase (EGF receptor), inhibition		Fluorescent assay	IC-50	1.30 nM	Pat. 1
Phase 1	<input type="checkbox"/> Erlotinib			Cancer remission/reduction, IN VITRO	Mitogenesis, inhibition	A16-F10 human cancer cells	Dye assay (MTT)	IC-50	20 nM	Ref. 1
Phase 1	<input type="checkbox"/> Erlotinib			EGFR (erbB1) inhibition, IN VITRO	Protein-tyrosine kinase (EGF receptor), inhibition			IC-50	24.6 ± 1.70 nM	Ref. 2
Phase 1	<input type="checkbox"/> Erlotinib			EGFR (erbB1) inhibition, IN VITRO	Protein-tyrosine kinase (EGF receptor) autophosphorylation, inhibition	Purified enzyme	Fluorescent assay	IC-50	30 nM	Ref. 1
Phase 1	<input type="checkbox"/> Erlotinib			Melanoma remission/reduction, IN VITRO	Mitogenesis, inhibition	G361 human melanoma cells	Dye assay (MTT)	IC-50	30.4 nM	Pat. 2
Phase 1	<input type="checkbox"/> Erlotinib			Cancer, prostate (adenocarcinoma)	Mitogenesis, inhibition	PC3 human prostate adenocarcinoma cells	Dye assay (MTT)	IC-50	35.3 nM	Pat. 2

Filter by Statistics

- ▶ **Biomarker**
- ▶ **Experimental Activity**
 - System
 - Activity/Effect
 - Target/Condition/Toxicity
- ▶ **Pharmacological Activity**
- ▶ **Parameter**
- ▶ **Material**
- ▶ **Method**
- ▶ **Reference Type**
- ▶ **Product in Studies**
- ▶ **Drug Mechanism of Action**
- ▶ **Administration Route**
- ▶ **Dose Regimen**
- ▶ **Experimental Model**
 - Species
 - Strain

Filter by Value Range

Mayo Clinic Cholangitis, sclerosing

Related Information

Drugs & Biologics	Biomarkers	Targets & Pathways	Literature	Patents	Organic Synthesis	Experimental Pharmacology
8	1088	1	3171	209	1	784
Experimental Models	Pharmacokinetics / Metabolism	Clinical Studies	Companies & Research Institutions	Disease Briefings		
16	1261	1438	15	9		



查看和Erlotinib结构相似的在研药物

Records Retrieved 1 in Drugs & Biologics Options

Drugs & Biologics

Structure Feature Options - Mozilla Firefox

integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_utils.show

Structure Feature Options

Structure Feature options include the ability to: copy the structure currently displayed back into your preferred structure editor (structure drawing tool); export the structure in molfile or SMILES format; view the molecular property information for a structure; and display a set of structurally related compounds setting the parameter to the desired degree of similarity.

- Copy structure to the Marvin applet structure editor.
- Copy structure to the Marvin structure editor inside Integrity.
- Export Molfile
- Export SMILES
- Display structurally similar compounds (80% default value can be modified manually).

STRUCTURE FEATURES

.HCl

METABOLITES

SALES

7,12-15H,8-11H2,2-3H3,

Molecular Mechanism EGFR (HER1; erbB1) Inhibitors

Cellular Mechanism Inhibitors of Signal Transduction Pathways

CP-358774
NSC-718781
OSI-774
R-1415
RG-1415
Ro-50-8231



查看类似结构药物，调阅比较药理学活性数据

Records Retrieved 55 Record(s) Retrieved

Drugs & Biologics Search Results

Entry Number: 404449 Drug Name: Highest Phase: Biological Te

Product Category	Therapeutic Group	Mechanism of Action
	Asthma Therapy	EGFR (HER1; erbB1)
	Oncolytic Drugs	Inhibitors of Signal Transduction Pathways

Standard InChI: 1S/C27H30N4O4/c1-6-18-8-7-9-19(14-18)30-25-21-/h1,7-9,14-17,20H,10-13H2,2-5H3,(

Standard InChIKey: QJQCSXAKSADYBA-UHFFFAOYSA-N

Structure Feature Options

Entry Number: 446953 Drug Name: Highest Phase: Biological Te

Product Category	Therapeutic Group	Mechanism of Action
		EGFR (HER1; erbB1)
		Inhibitors of Signal Transduction Pathways

Standard InChI: 1S/C26H28N4O4/c1-3-18-6-4-7-19(14-18)29-26-21-15-24(23(33-2)16-22(21)27-17-28-26)34-20-9-11-30(12-10-20)25(32)8-5-13-31/h1,4,6-7,14-17,20,31H,5,8-13H2,2H3,(H,27,28,29)

Standard InChIKey: VCCZAOHJZAECHL-UHFFFAOYSA-N

Structure Feature Options

Entry Number: 790203 Drug Name: Highest Phase: Biological Testing

Product Category	Therapeutic Group	Mechanism of Action	Organization
	Oncolytic Drugs	EGFR (HER1;	Beta Pharma

Options

- Keep Me Posted
- Export Center
- Integrity Reports
- Product List
- Display Milestones
- Gateways to Product Development Status
- Full Records
- References
- Patents
- All Related Information via Quick Search
- Printer Friendly Format

Filter by Statistics

- Development Status
- Organization
- Major Therapeutic Groups
- Therapeutic Group
- Major Condition Groups
- Condition
- Mechanistic Scope
 - Molecular Mechanisms
 - Cellular Mechanisms
- Major Product Categories
- Product Category
- Launch Year
- Target
- Under Active Development / No Development Reported
- Filter Only Lead Compounds
- Natural Source Categories
- Natural Source Scientific Name
- Prescription/ Indication Type
- Administration Route


链接到相关信息，专利，文献，靶标，药理，药代，临床试验等信息。

所有与上页药物相关的信息经过归类整理如下



You have entered the Quick Search feature. Click one of the Knowledge Areas containing results to access a list of the records retrieved by your Quick Search. To be shown which Knowledge Areas contain information related to the Knowledge Area you are in, click the adjacent Related Information icon.

Drugs & Biologics



相关的：药物；专利，药理 / 毒理试验数据；药代动力学试验数据；临床试验；相关靶标及路径；合成路线；代谢途径；公司相关信息；疾病总结；生物标志物

药理学活性数据，可以按照多种条件过滤比较

Records Retrieved 1230 in Experimental Pharmacology

Options

Experimental Pharmacology Search Results

1 2 3 4 5 6 7 8 9 10 [Next>] [Last>>]

Drug Name	Biomarker	Mechanism of Action	Experimental Activity	Pharmacological Activity	Material / Experimental	Method	Parameter	Value	Details
298493		EGFR (HER1; erbB1) Inhibitors	EGFR (erbB1) inhibition, IN VITRO	Protein-tyrosine kinase (EGF receptor), inhibition				£ 5.00 nM	Ref. 142
298493		EGFR (HER1; erbB1) Inhibitors	Fructose-Biphosphatase (Fructose-1,6-Bisphosphate; FBPase) inhibition, IN VITRO	Fructose-bisphosphatase inhibition				0.250 µM	Ref. 142
298493		EGFR (HER1; erbB1) Inhibitors	Fructose-Biphosphatase (Fructose-1,6-Bisphosphate; FBPase) inhibition, IN VITRO	Fructose-bisphosphatase, inhibition	Kidney, pig		IC-50	0.770 µM	Ref. 142
298493		EGFR (HER1; erbB1) Inhibitors	Fructose-Biphosphatase (Fructose-1,6-Bisphosphate; FBPase) inhibition, IN VITRO	Fructose-bisphosphatase, inhibition	Liver, rabbit		IC-50	> 10 µM	Ref. 142
298493		EGFR (HER1; erbB1) Inhibitors	Fructose-Biphosphatase (Fructose-1,6-Bisphosphate; FBPase) inhibition, IN VITRO	Fructose-bisphosphatase, inhibition	Liver, rat		IC-50	> 10 µM	Ref. 142
475319		EGFR (HER1; erbB1) Inhibitors	EGFR (erbB1) inhibition, IN VITRO	Protein-tyrosine kinase (EGF receptor), inhibition	Human enzyme	Fluorescent assay	IC-50	£ 0.100 µM	Pat. 22
475319		EGFR (HER1; erbB1) Inhibitors	HER2 (erbB2; HER2/neu) inhibition, IN VITRO	Protein-tyrosine kinase (ErbB2/HER2),			IC-50	0.100 - 1.00 µM	Pat. 22

检索结果进行分析：可以按照实验活性、药理学活性、参数、实验材料、实验方法等等

Filter by Statistics

- ▶ **Biomarker**
- ▶ **Experimental Activity**
 - System
 - Activity/Effect
 - Target/Condition/Toxicity
- ▶ **Pharmacological Activity**
- ▶ **Parameter**
- ▶ **Material**
- ▶ **Method**
- ▶ **Reference Type**
- ▶ **Product in Studies**
- ▶ **Drug Mechanism of Action**
- ▶ **Administration Route**
- ▶ **Dose Regimen**
- ▶ **Experimental Model**
 - Species
 - Strain

Filter by Value Range

比较不同化学结构的药理学活性



Records Retrieved 9708 in Experimental Pharmacology

Experimental Pharmacology Search Results

1 2 3 4 5 6 7 8 9 10 [Next>] [Last>>]

Query > Include Literature Results = Y AND Include Patent Results = Y AND Pharmacological Activity = "Cytotoxicity @ 24 h" AND Chemical Source (Y/II) = Y

Drug Name	Biomarker	Mechanism of Action	Experimental Activity	Pharmacological Activity	Chemical Source	Parameter	Value	Details	
<input type="checkbox"/> (+)-2,3,9-Trimethoxypterocarpan		Caspase 3 Activators	Leukemia, acute promyelocytic (M3) remission/reduction, IN VITRO	Cytotoxicity @ 24 h		CC-50	0.100 mM	Ref. 1	
<input type="checkbox"/> (+)-2,3,9-Trimethoxypterocarpan		Caspase 3 Activators	Leukemia, T-cell acute lymphocytic remission/reduction, IN VITRO	Cytotoxicity @ 24 h		CC-50	0.600 mM	Ref. 1	
<input type="checkbox"/> (+)-2,3,9-Trimethoxypterocarpan		Caspase 3 Activators	Digestive/gastrointestinal cancer remission/reduction, IN VITRO	Cytotoxicity @ 24 h		CC-50	0.600 mM	Ref. 1	
<input type="checkbox"/> (+)-2,3,9-Trimethoxypterocarpan		Caspase 3 Activators	Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO	Cytotoxicity @ 24 h		CC-50	0.700 mM	Ref. 1	
<input type="checkbox"/> (+)-2,3,9-Trimethoxypterocarpan		Caspase 3 Activators	Melanoma remission/reduction, IN VITRO	Cytotoxicity @ 24 h		CC-50	2.90 mM	Ref. 1	
<input type="checkbox"/> (+)-9'-Isovaleroylaricresinol			Digestive/gastrointestinal cancer remission/reduction, IN VITRO	Cytotoxicity @ 24 h		CC-50	5.30 µM	Ref. 2	
<input type="checkbox"/> (+)-9'-Isovaleroylaricresinol			Cancer, prostate (adenocarcinoma) remission/reduction, IN VITRO	Cytotoxicity @ 24 h	PC3 human prostate adenocarcinoma cells	Dye assay (MTT)	CC-50	8.10 µM	Ref. 2
<input type="checkbox"/> (+)-Catechin		Fatty Acid Synthase Inhibitors LDL Antioxidants Nav1.5		Cytotoxicity @ 120 h	MRC5 human embryonic lung fibroblasts	Dye assay	CC-50	> 75 µM	Ref. 4

Options

- Export Center
- Integrity Reports
- Structure Activity**
- Information via Quick Search
- Calculate Mean/Median Values
- Unify Parameter to Non-Log Form
- Unify Parameter to Log Form
- Convert Molar Units to Grams
- Convert Grams to Molar Units
- References
- Patents
- Printer Friendly Format

Filter by Statistics

- Biomarker
- Experimental Activity
 - System Activity/Effect
 - Target/Condition/Toxicity
- Pharmacological Activity
- Parameter
- Material
- Method
- Reference Type
- Product in Studies
- Drug Mechanism of Action
- Administration Route
- Dose Regimen

Filter by Value Range

查看SAR及具体的活性数据，指导结构式优化


Records Retrieved 1230 in Experimental Pharmacology

Experimental Pharmacology Search Results

Experimental Activity: 5-Hydroxytryptamine Receptors affinity, IN VITRO

Pharmacological Activity: Serotonin 5-HT receptors affinity


Parameter: IC-50

Drug Name & Structure	Mechanism of Action	Material	Value	Details
<input type="checkbox"/> CUDC-101 	EGFR (HER1; erbB1) Inhibitors Apoptosis Inducers Histone Deacetylase (HDAC) Inhibitors HER2 (erbB2) Inhibitors		> 10 μM	Ref. 2

Experimental Activity: ABCB1 (P-Glycoprotein, MDR-1) inhibition, IN VITRO

Pharmacological Activity: P-Glycoprotein [MDR1], inhibition

Parameter: IC-50

Drug Name & Structure	Mechanism of Action	Material	Method	Value	Details
<input type="checkbox"/> Erlotinib hydrochloride 	EGFR (HER1; erbB1) Inhibitors Inhibitors of Signal Transduction Pathways	MDCK Madin-Darby canine kidney epithelial cells (MDR1-overexpressing)	Calcein-AM uptake assay	19.1 ± 7.22 μM	Ref. 9

Parameter: MIC

Options





-  **Export Center**
-  **Experimental Pharmacology Data**
-  **References**
-  **All Related Information via Quick Search**
-  **Printer Friendly Format**

1 2 3 4 5 6 7 8 9 10 [Next>] [Last>>]



方便导出整理好的表格，比较更容易

export(15) - Microsoft Excel

	C	E	F	H	I	L	Y
	Parameter	Drug Name	Structure	Mechanism of	Material	String Value	Target/Condition/Toxicity
1	IC-50	CUDC-101		(HER1; erbB1) Inhibitors; Inhibitors of Signal Transduction Pathways		> 10 μM	5-Hydroxytryptamine Receptors
2	IC-50	Erlotinib hydrochloride	 .HCl	EGFR (HER1; erbB1) Inhibitors; Inhibitors of Signal Transduction Pathways	MDCK Madin-Darby canine kidney epithelial cells (MDR1-overexpressing)	19.1 ± 7.22 μM	ABCB1 (MDR-1)
3	MIC	Erlotinib hydrochloride	 .HCl	EGFR (HER1; erbB1) Inhibitors; Inhibitors of Signal Transduction Pathways	A549 human non-small-cell lung carcinoma cells (paclitaxel-resistant)	1.00 μM	ABCB1 (MDR-1)
4	MIC	Erlotinib hydrochloride	 .HCl	EGFR (HER1; erbB1) Inhibitors; Inhibitors of Signal Transduction Pathways	DLKP human metastatic lung carcinoma	5.00 μM	ABCB1 (MDR-1)



快速概览特定领域的研发进展和布局

- 肝癌领域的当前在研药物研发进展和布局
- 结构式检索举例

Integrity结构式检索

The screenshot displays the Thomson Reuters Integrity search interface. On the left, a 'Knowledge Area' menu is visible, with 'Targets & Pathways' highlighted. The main search area features a 'Quick Search' bar and an 'Advanced Search' section. Below this, there are several filter categories: 'Lead Compounds' and 'Under Active Development', 'Reference', 'Targets & Pathways', and 'Patent'. Each category includes a 'Select Value' dropdown and two 'Optional Value' dropdowns. To the right of each filter section are three 'Index AND' buttons. A text box with an orange border is overlaid on the interface, containing the text: '除了Genomics/Targets & Pathways 和Biomarker模块之外，均可结构式检索。点击Structure Search打开结构式检索框'.

除了Genomics/Targets & Pathways 和Biomarker模块之外，均可结构式检索。点击Structure Search打开结构式检索框

Integrity结构式检索

Knowledge Areas QuickSearch 90 Home Support/Help Query Manager/Alert Center Reports

126618 Records in Patents

Click below to display the most recent patent information for each Condition, updated each Monday

Conditions

- ▶ Pain
- ▶ Psychiatric Disorders
- ▶ Neurological Disorders
- ▶ Respiratory Disorders
- ▶ Cardiovascular Disorders
- ▶ Hematologic Diseases
- ▶ Genitourinary Disorders
- ▶ Gastrointestinal Disorders
- ▶ Nutrition disorders
- ▶ Endocrine Disorders
- ▶ Infections
- ▶ AIDS
- ▶ Musculoskeletal and Connective Tissue Disorders
- ▶ Immunological Disorders
- ▶ Metabolic Diseases
- ▶ Cancer
- ▶ Other disorders (Systemic disorders)

▶ All Conditions

▶ Click here to display today's featured patent family entries in Integrity

Learning center

- Combining Chemical Structure and Patent Criteria for Drugs and Biologics

Advanced Search Session History Clear Form Start

Structure Search Options Structure Search

Search Type

- Substructure
- Exact Structure
- Similarity (0-100%) 80


Structure Representation

- Normal
- Standardized

Search Options

- Match Stereochemistry

[Guide to Structure Search Options](#)




You are using the ChemAxon Marvin Applet structure drawing tool.

[Click here to change to another structure editor.](#)

Patent

结构式检索指南



Searches run in *Integrity* on structures drawn with
Symyx Draw, Symyx MDL ISIS/Draw + Symyx MDL Chime, ChemAxon
Marvin Applet, CambridgeSoft CS ChemDraw Plugin

Structure search types

Exact Structure Search

- In the case of exact structure searching, all molecules that are isomorphic with the query are returned.
- Includes exact topology matching: the whole molecular graph must match (Implicit and explicit hydrogens are treated equally.)
- Ignores exact stereo matching: queries allowed.
- Ignores exact atom types

Substructure Search

- Substructure search
- Query

Similarity Search

- Similarity search
- The canonical

Integrity 兼容4种结构式编辑器：Symyx Draw, Symyx MDL ISIS Draw, ChemAxon Marvin Applet and CambridgeSoft CS ChemDraw 进行结构式检索。点击相应的链接选择最适合您的结构式编辑器。另外，您可以在这里找到下载 Chemdraw插件和订购SYMx 编辑器的链接。

- the fingerprint of the molecule in the database

切换结构式检索插件

The screenshot displays the ChemAxon Marvin web interface. At the top, there is a navigation bar with "Knowledge Areas", "QuickSearch", and various utility links like "Home", "Support/Help", "Query Manager/Alert Center", and "Reports". Below this, the main content area is divided into sections. On the left, a sidebar shows "126618 Records in Patents" and a list of "Conditions" including Pain, Psychiatric Disorders, Neurological Disorders, Respiratory Disorders, Cardiovascular Disorders, Hematologic Diseases, Genitourinary Disorders, Gastrointestinal Disorders, Nutrition disorders, Endocrine Disorders, Infections, AIDS, Musculoskeletal and Connective Tissue Disorders, Immunological Disorders, Metabolic Diseases, Cancer, and Other disorders (Systemic disorders). A "Learning center" section at the bottom left offers a link to "Combining Chemical Structure and Patent Criteria for Drugs and Biologics".

The central part of the interface features "Advanced Search" and "Session History" tabs. Below these are "Structure Search Options" and "Structure Search" tabs. The "Structure Search Options" section includes three columns of settings: "Search Type" with radio buttons for "Substructure" (selected), "Exact Structure", and "Similarity (0-100%)" with a text input field containing "80"; "Structure Representation" with radio buttons for "Normal" (selected) and "Standardized"; and "Search Options" with a checkbox for "Match Stereochemistry" which is currently unchecked. A link "Guide to Structure Search Options" is provided below these settings.

Below the search options is a "ChemAxon Marvin Applet structure drawing tool". The tool's interface includes a menu bar (File, Edit, View, Insert, Help) and a toolbar with icons for drawing atoms (H, C, N, O, F, P, S, Cl, Br, I), bonds (single, double, triple), and rings (pentagon, hexagon, benzene, naphthalene). A text box at the bottom of the applet window contains the message: "You are using the ChemAxon Marvin Applet structure drawing tool. [Click here to change to another structure editor.](#)"

结构式检索插件切换及下载

注：第三种ChemAxon 是基于在线的插件，无需另行下载安装

Select a Structure Editor from the list below. - Windows Internet Explorer

https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_self_reg_change_csplugin

THOMSON REUTERS
Integrity SM
Empowering knowledge-based drug

Select a Structure Editor from the list below.

[Accelrys Draw](#) *

[ChemAxon Marvin Applet](#)

[ChemDraw™ Plugin](#) ***

Loading the Marvin Applet and Accelrys Draw in the same browser session provokes Java conflicts. Please restart your browser after changing from one of these structure editors to the other in the same session. When you re-enter Integrity, the last editor chosen will be the default structure editor.

*To use Accelrys Draw for chemical structure drawing, you must have an Accelrys Draw license (visit <http://accelrys.com/> for more information).

**To use ISIS/Draw for chemical structure drawing, you must have an ISIS/Draw license (visit <http://accelrys.com/> for more information) to download and install the Accelrys Chime plugin at no charge ([click here](#)).

***Click [here](#) to download the CambridgeSoft CS ChemDraw™ Net Plugin for Windows at no charge, and [here](#) for Mac.

切换结构式检索插件

下载第三方结构式检索插件

完成 Internet 100%

Knowl

Knowledge Areas

Quick Search

go

Home

Support/Help

Query Manager/Alert Center

Reports

304895 Records in Drugs & Biologics
284760 Records with chemical structure
342725 Records in
319553 Records with

Advanced Search

Session History

Clear Form

Start

Structure Search Options

Structure Search

The Starting Line

A selection of new m...

Search Type

Structure Representation

Search Options

The Starting Li

A selection of new m...
targets ready to enter

Pipeline on the

Milestones for drugs...
development.

Gatew
Developm

Select a condition...
program status list
launched or under
for that condition.

- ▶ AIDS
- ▶ Anesthesia
- ▶ Cancer
- ▶ Cardiovascul
- ▶ Congenital d
- ▶ Critical care
- ▶ Dermatologi
- ▶ Diagnostics
- ▶ Disorders of
- ▶ Function and
- ▶ Ear Disorder
- ▶ Endocrine Di
- ▶ Eye Disorder
- ▶ Gastrointest
- ▶ Genetic Diso
- ▶ Genitourinar
- ▶ Hematologic
- ▶ Immunologic

添加至检索框

ISIS/Drug... [6 Integrity B.../Plugin]

File Edit View Options Project Data Properties Chemistry Window Help

Optional Value

Index AND

342725 Records in Drugs & Biologics
319553 Records with chemical structure

The Starting Line

A selection of new molecular entities and targets ready to enter the R&D arena.

Pipeline on the Move

Milestones for drugs under active development.

Gateways to Development Status

Select a condition to generate a program status list for compounds launched or under active development for that condition.

Lookup

- ▶ AIDS
- ▶ Anesthesia
- ▶ Cancer
- ▶ Cardiovascular Disorders
- ▶ Congenital defects
- ▶ Critical care medicine
- ▶ Dermatological Disorders
- ▶ Diagnostics
- ▶ Disorders of Sexual Function and Reproduction
- ▶ Ear Disorders
- ▶ Endocrine Disorders
- ▶ Eye Disorders
- ▶ Gastrointestinal Disorders
- ▶ Genetic Disorders
- ▶ Genitourinary Disorders
- ▶ Hematologic Diseases
- ▶ Immunological Disorders
- ▶ Infections
- ▶ Metabolic Diseases
- ▶ Mouth and Salivary Glands Disease
- ▶ Musculoskeletal and

Advanced Search

Session History

Clear Form

Start

Structure Search Options

Structure Search

Search Type

Substructure

Exact Structure

Structure Representation

Normal

Standardized

Search Options


Match Stereochemistry

Select Value

80

Select Value

- Entry Number
- Drug Name
- Chemical Name / Description
- Standard InChI
- Standard InChIKey
- CAS Registry No.
- Molecular Formula
- Molecular Weight
- Highest Phase
- Year Launched / Registered
- Organization
- Organization (+ Related Orgs.)
- Condition
- Therapeutic Group
- Mechanism of Action
- Product Category
- Prescription/Indication Type
- New Molecular Entity (Y/N)
- Metabolites (Y/N)
- Natural Source (Y/N)
- ⊕ Development Status
- ⊕ Milestone
- ⊕ Natural Source
- Last Updated
- Available Since



可以是最终产物，
也可以是中间体

可以与其他条件一起组合检索式

Double-click in the structure drawing window above to launch Symyx MDL ISIS/Draw. When you have drawn the structure, click Transfer to copy the structure into the Integrity Structure Drawing Window.

[Click here to change to another structure editor.](#)

Active Development

Index AND

进入Knowledge Areas-Organic Synthesis

THOMSON REUTERS
IntegritySM

Organic Synthesis

Knowledge Areas

- Drugs & Biologics
- Targets & Pathways
- Genomics
- Biomarkers
- Organic Synthesis**
- Experimental Pharmacology
- Experimental Models
- Pharmacokinetics/Metabolism
- Clinical Studies
- Disease Briefings
- Companies & Research Institutions
- Literature
- Patents

Quick Search go Home Support/Help Query Manager / Alert Center Reports

Advanced Search Session History Clear Form Start

Organic Synthesis Structure Search

Display Schemes Intermediates Reagents

Select Value Optional Value Optional Value

Index AND Index AND Index AND

Product

Lead Compounds Under Active Development

Select Value Optional Value Optional Value

Index AND Index AND Index AND

Reference

Select Value Optional Value Optional Value

Index AND Index AND Index AND

Patent

打开结构式检索

画出结构式，或插入以前保存的结构式，以萆为例

THOMSON REUTERS
IntegritySM Organic Synthesis

Knowledge Areas Quick Search Home Support/Help Query Manager/Alert Center Reports

THOMSON REUTERS
IntegritySM Organic Synthesis

Knowledge Areas Quick Search go Home Support/Help Query Manager/Alert Center Reports

24033 Records in Organic Synthesis

Advanced Search Session History Clear Form **Start**

Structure Search Options Structure Search

Search Type

- Substructure
- Exact Structure
- Similarity (0-100%)


Structure Representation

- Normal
- Standardized

Search Options

- Match Stereochemistry

[Guide to Structure Search Options](#)

CC1=CCCC(C)C1

包含茛菪子结构为中间体的合成路线298条，调阅终端药物

Records Retrieved

Records

Records Retrieved

1 Record retrieved


Options

Schemes Results List: 298 Schemes

Query > Structure Search =

Scheme Full Records

Scheme Number 301519-01-a
 End Product [\(-\)-2-\(2-Bromohexadecanoyl\)paclitaxel](#)



Filter by Statistics

- ▶ Drug Name
- ▶ Development Status
- ▶ Organization
- ▶ Major Therapeutic Group
- ▶ Therapeutic Group
- ▶ Major Condition
- ▶ Condition
- ▶ Mechanistic Scope
 - Molecular Mechanism
 - Cellular Mechanism
- ▶ Under Active Development / No Development Reported
- ▶ Natural Product Y/N

Statistics

US

Group

anism

ism

ported
/N

包含帖子结构为中间体的合成路线298条，调阅终端药物

Records Retrieved Records 1 to 25 of 113 retrieved

Options

- Save Query
- Export Center
- Integrity Reports
- Scheme Full Records
- Intermediate List
- Reagent List
- All Related Information via Quick Search
- Printer Friendly Format

Schemes Results List: 298 Schemes relating to 113 End Products

Query > Structure Search =

	Schemes	End Product	Intermediates	Reagents		
<input type="checkbox"/>	1	(-)-2-(2-Bromohexadecanovl)paclitaxel	2	1		
<input type="checkbox"/>	1	2'-Palmitovlpaclitaxel	2	1		
<input type="checkbox"/>	1		1	2		
<input type="checkbox"/>	2		2	2		
<input type="checkbox"/>	1		3	4		
<input type="checkbox"/>	1	270079	7	4	0	1
<input type="checkbox"/>	2	275579	10	12	0	1
<input type="checkbox"/>	2	275580	9	8	0	1
<input type="checkbox"/>	1	279798	8	8	0	1
<input type="checkbox"/>	1	281066	6	3	0	2
<input type="checkbox"/>	1	286137	4	7	1	1
<input type="checkbox"/>	1	299805	12	18	0	2

调阅和这些路线有关的终端药物

Filter by Statistics

- Drug Name
- Development Status
- Organization
- Major Therapeutic Group
- Therapeutic Group
- Major Condition
- Condition
- Mechanistic Scope
 - Molecular Mechanism
 - Cellular Mechanism
- Under Active Development / No Development Reported
- Natural Product Y/N

查看终端药物



You have entered the Quick Search feature. Click one of the Knowledge Areas containing results to access a list of the records retrieved by your Quick Search. To be shown which Knowledge Areas contain information related to the Knowledge Area you are in, click the adjacent Related Information icon.

Organic Synthesis

Knowledge Area	Records	Related Info
Drugs & Biologics	104	RELATED INFO
Biomarkers	0	RELATED INFO
Literature	140	RELATED INFO
Organic Synthesis	298	RELATED INFO
Pharmacokinetics/ Metabolism	0	RELATED INFO
Companies & Research Institutions	0	RELATED INFO
Experimental Models	0	RELATED INFO
RELATED INFO	0	Targets & Pathways
RELATED INFO	0	Genomics
RELATED INFO	122	Patents
RELATED INFO	0	Experimental Pharmacology
RELATED INFO	0	Clinical Studies
RELATED INFO	0	Disease Briefings

使用Filter by查看终端药物所处阶段和所属公司

Records Retrieved

104 in Drugs & Biologics Search Results

Options

Drugs & Biologics Search Results

1 2 3 4 5 6 7 8 9 10 [Next>] [Last>>]

Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Mechanism of Action	Organization
<input type="checkbox"/> 070003	Launched-1955		Methylprednisolone	Medrol Urbason		Imperial College Jiangsu Province Hospital of TCM Pfizer (Originator) Sanofi Vilnius University
<input type="checkbox"/> 090214	Phase III	KM-2210	Atrimustine Bestrabucil Busramustine	Kregan	Steroids	Kureha (Originator)
<input type="checkbox"/> 090412	Phase III	Win-32729	Epostane		Progesterone Receptor Antagonists	Sanofi (Originator)
<input type="checkbox"/> 090670	Phase II	4-HPR HPR McN-R-1967 NSC-374551 ST-602 SYT-101	Fenretinide		Retinoids	Cancer Research UK CerRx Department of Veterans Affairs Janssen Research & Development (Originator) M.D. Anderson Cancer Center National Cancer Institute (NCI) (Originator)

按照终端药物所处阶段进行分析

Filter by Statistics

Development Status

Organization

Major Therapeutic Groups

Therapeutic Group

Major Condition Groups

Condition

Mechanistic Scope

Molecular Mechanisms

Cellular Mechanisms

Major Product Categories

Product Category

Launch Year

Therapeutic Impact and Organization (3D chart)

Target

Under Active Development / No Development Reported

Condition and Phase (3D chart)

Filter Only Lead Compounds

Natural Source Categories

Natural Source Scientific Name

Prescription/ Indication Type

终端药物所处阶段分析



Export to Excel




Snapshot Tool

Development Status

Query definition not available for this operation.

...



Display Options

Horizontal Display | Vertical Display | Pie Chart Display

View Subset(s)

Print Chart

Help

分析拥有II期以上临床药物的公司和机构

Records Retrieved

30 in Drugs & Biologics Search Results

Options

Drugs & Biologics Search Results

1 2 3

Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Mechanism of Action	Organization
<input type="checkbox"/> 070003	Launched-1955		Methylprednisolone	Medrol Urbason		Imperial College Jiangsu Province Hospital of TCM Pfizer (Originator) Sanofi Vilnius University
<input type="checkbox"/> 090214	Phase III	KM-2210	Atrimustine Bestrabucil Busramustine	Kregan	Steroids Oncolytic Drugs	Kureha (Originator)
<input type="checkbox"/> 090412	Phase III	Win-32729	Epostane		Progesterone Receptor Antagonists	Sanofi (Originator)
<input type="checkbox"/> 090670	Phase II	4-HPR HPR McN-R-1967 NSC-374551 ST-602 SYT-101	Fenretinide		Retinoids	Cancer Research UK CerRx Department of Veterans Affairs Janssen Research & Development (Originator) M.D. Anderson Cancer Center National Cancer Institute (NCI) (Originator)

按照终端药物所属机构进行分析

Filter by Statistics

- Development Status
- Organization**
- Major Therapeutic Groups
- Therapeutic Group
- Major Condition Groups
- Condition
- Mechanistic Scope
 - Molecular Mechanisms
 - Cellular Mechanisms
- Major Product Categories
- Product Category
- Launch Year
- Therapeutic Impact and Organization (3D chart)
- Target
- Under Active Development / No Development Reported
- Condition and Phase (3D chart)
- Filter Only Lead Compounds
- Natural Source Categories
- Natural Source Scientific Name
- Prescription / Indication

机构组织分析：


台湾长庚大学；中科院；浸会大学
医学技术学院.....

 **Export to Excel**

 **Snapshot Tool**

Organization

Natural Source (Y/N) = Y AND Structure Search =



Display Options

- Horizontal Display
- Vertical Display
- Pie Chart Display

-  **View Subset(s)**
-  **Print Chart**
-  **Help**



提纲

- Thomson Reuters Integrity数据库简介
- Integrity解决如下问题
 - 动态监测新分子实体和新靶标
 - 快速概览特定领域的研发进展和布局
 - 选题立项评估药物品种的综合状况
 - 比较药理学活性进行结构式优化
 - 一站式概览疾病综述和主流药物
 - 设置专属Email跟踪获取更新内容
- Q &A

Disease Briefings 左边直接查看或右边检索

THOMSON REUTERS
Intearity

140 Records in Disease Briefings

Click a specialty below for a list of related Disease Briefings

- ▶ Autoimmune Disorders
- ▶ Bioterrorism
- ▶ **Cancer**
- ▶ Cardiovascular Disorders
- ▶ Critical Care Medicine
- ▶ Dermatological Disorders
- ▶ Endocrine Disorders
- ▶ Eye Disorders
- ▶ Gastrointestinal Disorders
- ▶ Genetic Disorders
- ▶ Genitourinary Disorders
- ▶ Hematologic Diseases
- ▶ Immunological Disorders
- ▶ Infections
- ▶ Men's Health
- ▶ Metabolic Diseases
- ▶ Musculoskeletal and Connective Tissue Disorders
- ▶ Neurological Disorders
- ▶ Pain
- ▶ Poisoning
- ▶ Psychiatric Disorders
- ▶ Rare Diseases
- ▶ Reproductive Health
- ▶ Respiratory Disorders
- ▶ Substance Abuse and Dependence
- ▶ Women's Health

Knowledge

- Drugs & Biologics
- Targets & Pathways
- Genomics
- Biomarkers
- Organic Synthesis
- Experimental Pharm
- Experimental Mode
- Pharmacokinetics/M
- Clinical Studies
- Disease Briefings**
- Companies & Rese
- Literature
- Patents

Advanced Search Session History Clear Form Start

Disease Briefings

Disease Briefing	▶ "Lung Cancer"	Index	AND ▶
Optional Value	▶	Index	AND ▶
Optional Value	▶	Index	AND ▶

Product Structure Search

Lead Compounds Under Active Development

Select Value	▶	Index	AND ▶
Optional Value	▶	Index	AND ▶
Optional Value	▶	Index	AND ▶

药物报告直接链接查看疾病综述

Records Retrieved

1 in Drugs & Biologics

Options

Drugs & Biologics Search Results

1

<input type="checkbox"/> Entry Number	90519	UPDATES	Chemical Structure	STRUCTURE FEATURES	
Record Creation Date	Jun 13, 2002				
Last Updated Date	Apr 06, 2013				
CAS Registry No.	84625-61-6				
Molecular Formula	C ₂₅ H ₃₈ Cl ₂ N ₈ O ₄				
Molecular Weight	478.55				
Highest Physiological Activity	Records Retrieved 7 Record(s) Retrieved				
Physical Properties					
Under Active Development	Disease Briefing	Related Products			
	Lung Cancer	Display Related Products (262)			
	Current Lung Cancer Pipeline				
	Angiogenesis Inhibitors				
	Agents Targeting Signal Transduction Pathways				
Chemical ID	Prostate Cancer	Display Related Products (230)			
(±)-4-[4-[4-(1-yl)phenyl]	Angiogenesis Inhibitors				
	Signal Transduction Modulators				
	Current Prostate Cancer Pipeline				
	Fungal Infections: Dermatomycoses	Display Related Products (39)			
	Treatment				
	Fungal Infections: Candidiasis	Display Related Products (34)			
	Treatment				
	Fungal Infections: Aspergillosis	Display Related Products (10)			
	Treatment				
	Fungal Infections: Endemic Mycoses	Display Related Products (11)			
	Treatment				
	Fungal Infections: Cryptococcosis	Display Related Products (10)			
	Treatment				
Code name	JK-1211			Itraconazole (BAN; USAN; Rec INN)	Canadiol



了解疾病研发历史、重要靶标、主流药物、治疗方法等，申请基金或课题时作为课题背景信息来源

• 肺癌的流行病学数据

Lung Cancer

Facts about Lung Cancer

- Classification
- Risk Factors
- Epidemiology
- Morbidity and Mortality
- Cost

Diagnosis

Prevention

Epidemiology

According to the International Agency for Research on Cancer's GLOBOCAN 2008 database, lung cancer is the most important cancer in the world today, both in terms of the total number of individuals it affects (1.6 million new cases in 2008) and the total number of resulting deaths (1.4 million in 2008) (Jemal, A. et al., 2011). The mortality-to-incidence ratio for lung cancer is extraordinarily high: 0.87. Lung cancer is the most common type of cancer among men worldwide, with an incidence rate of 35.5 per 100,000. It is less common among women, for whom the global incidence is 12.1 per 100,000.

Cancer Cases by Site and Gender (Animated Chart)

2008年，全球新增160万肺癌病例，140万死亡病例，死亡-发病比率高达0.87。肺癌已经成为当今世界最重要的癌症。2008年，新增病例发展

Cost

According to the U.S. National Institutes of Health, the cumulative national healthcare costs associated with lung cancer care in 2010 totaled USD 12.12 billion. By 2020, this figure is predicted to reach USD 14.73 billion (Mariotto, A.B. et al., 2011).

A study was conducted to more precisely determine the economic burden associated with lung cancer. A database containing financial information on inpatient, outpatient and drug claims for a large number of individuals was analyzed and costs incurred by lung cancer patients were compared to those for controls with no cancer. Lung cancer patients consistently made greater use of health care services and incurred greater costs in concept of outpatient visits, emergency room visits, laboratory and radiology services and pharmaceuticals as compared to controls. The monthly total cost for each lung cancer patient was calculated to be USD 6,520, as compared to USD 339 for controls. Over the study period, which began at time of diagnosis and lasted until time of death or for a maximum of two years, total healthcare costs incurred were USD 45,897 per lung cancer patient, as compared to USD 2,907 per healthy control. Treatment costs were significantly higher among patients who failed on initial treatment, underlining the importance of effective first-line therapy (Kutikova, L. et al., 2005). A Spanish study has similarly calculated the per-patient costs associated with non-small cell lung cancer in that country. For patients with advanced or metastatic NSCLC, total cost from start of therapy to death ranged from EUR 11,300 to EUR 32,750, depending upon the treatment regimen employed (Isla, D. et al., 2011).

Rela

European men than women, and the highest rates are registered in Hungary, Poland, Czechia, Belgium, the Netherlands, Luxembourg, Italy, Denmark and Greece (O'Connor, S.J., 2011). In the U.K., 40,405 cases of lung cancer were reported in 2010; 86% of these were directly attributable to tobacco smoke (Parkin, D.M., 2011).

common among

Drugs & Biologics (242)



Literature (390)

深入研究疾病相关靶标通路，指导药物开发和设计

- 与肺癌治疗相关的代谢通路和重要靶点

5-Lipoxygenase

5-Lipoxygenase is an enzyme that catalyzes the first step in the conversion of arachidonic acid (AA) into leukotrienes (LTs), which primarily act as mediators of inflammatory and allergic reactions. 5-Lipoxygenase activity is regulated in a complex manner and involves different signaling pathways. It can be activated by an increase in intracellular Ca^{2+} concentration, diacylglycerols, phosphorylation by MAPKAP kinase-2 and ERK, while protein kinase A and glutathione peroxidase have been found to suppress its function. 5-Lipoxygenase inhibitors, which block the synthesis of hydroperoxide acid, 5-HPETE and subsequent synthesis of leukotrienes, may be effective in the management of COPD, atherosclerosis, cancer and rheumatoid arthritis (Loetzer, K. et al., 2005; Rådmark, O. and Samuelsson, B., 2005; Werz, O. and Steinhilber, D., 2005).



Lung Cancer targetscape. A diagram showing an overall cellular and molecular landscape or comprehensive network of connections among the current therapeutic targets for the treatment of lung cancer and their biological actions. Arrow: positive effect; dash: negative effect. Gray or lighter symbols are targets that are not validated (i.e., targets not associated with a product that is currently under active development for lung cancer).

治疗肺癌主流药物，主要机构/公司

Records Retrieved 264 in Drugs & Biologics Search Results

Options

Products related to Disease Briefing 43 - Lung Cancer

Keep Me Posted 9 10 [Next>] [Last>>]

Export Center

Integrity Reports

Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Product Category	Organization
<input type="checkbox"/> 090519	Launched-1988	JK-1211 R-51211	Itraconazole (BAN; USAN; Rec INN)	Canadiol Hyphanox	Triazoles	Janssen (Originator)

Drugs & Biologics

Drugs & Biologics 264 RECORDS RELATED INFO RELATED INFO 201 RECORDS Targets & Pathways

Records Retrieved 450 in Companies & Research Institutions

Options

Companies & Research Institutions Search Results 1 2 3 4 5 6 7 8 9 10 [Next>] [Last>>]

Organization	Website	Year	Annual Sales (M)
<input type="checkbox"/> A&G Pharmaceutical	www.agrx.net		
<input type="checkbox"/> APT Pharmaceuticals	www.aptbio.com		
<input type="checkbox"/> AVEO Pharma (d/b/a AVEO Oncology)	www.aveooncology.com		
<input type="checkbox"/> AbbVie	www.abbvie.com	2011	USD 17444
<input type="checkbox"/> Abbott	www.abbott.com	2011	USD 21407
<input type="checkbox"/> Ability Pharmaceuticals	www.abilitypharma.com		
<input type="checkbox"/> Acrostak	www.acrostak.com		
<input type="checkbox"/> Acusphere	www.acusphere.com		
<input type="checkbox"/> Aduro BioTech	www.adurobiotech.com		
<input type="checkbox"/> Advanomics	www.advanomics.com		
<input type="checkbox"/> Aduonchen Laboratories	www.aduonchen.com		

0908

勿林路远

肺癌的各种指南

The image shows a screenshot of the IntegriCity website, which is a platform for medical journals and guidelines. The main navigation bar includes 'Knowledge Areas', 'Quick Search', and 'Disease Briefings'. A sidebar on the left is titled 'Lung Cancer' and contains several categories: 'Facts about Lung Cancer', 'Diagnosis', 'Prevention', 'Treatment', 'Targets for Therapeutic Intervention', 'Latest Headlines', and 'Glossary of Terms'. Below these are 'Links' (including 'Links to Related Websites', 'Links to Selected Publications', and 'Links to Guidelines', which is highlighted with a red box) and 'Related Info' (including 'Drugs & Biologics (290)' and 'Literature (201)').

The main content area is titled 'Links to Guidelines' and lists several resources:

- Diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines (3rd Edition) (American College of Chest Physicians, May 2013)**
<http://journal.publications.chestnet.org/issue.aspx?journalid=99&issueid=926876>
- American Cancer Society lung cancer screening guidelines (American Cancer Society, 2013)**
<http://onlinelibrary.wiley.com/doi/10.3322/caac.21172/pdf>
- Cancer screening in the United States, 2013: A review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer**
<http://onlinelibrary.wiley.com/doi/10.3322/caac.21174/pdf>
- Guideline on the evaluation of anticancer medicinal products**
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/01/WC500137128.pdf
- Providing guidance for lung cancer screening: The American Association, April 2012)**
<http://www.lung.org/finding-cures/research-news/new-screening-guidelines/lung-cancer-screening.pdf>
- Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines**
http://annonc.oxfordjournals.org/content/23/suppl_7/vii56.full
- Guidance for industry: Clinical trial endpoints for the approval of drugs for the treatment of lung cancer (FDA, June 2011)**
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM259421.pdf>
- Lung cancer: The diagnosis and treatment of lung cancer (NICE, 2011)**
<http://www.nice.org.uk/nicemedia/live/13465/54202/54202.pdf>
- NCCN clinical practice guidelines in oncology: Small cell lung cancer**
<http://www.nccn.org/content/9/10/1086.full.pdf+html>
- 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guidelines for the treatment of non-small-cell lung cancer (American Society of Clinical Oncology, 2011)**
<http://jco.ascpubs.org/content/29/28/3825.full>
- Early stage and locally advanced (non-metastatic) non-small-cell lung cancer (European Society for Medical Oncology, 2010)**
http://annonc.oxfordjournals.org/content/21/suppl_5/v103.full

The right side of the screenshot shows the 'AMERICAN COLLEGE OF CHEST PHYSICIANS' website. The main header reads 'CHEST JOURNAL Official Publication of the American College of Chest Physicians'. Below this is a navigation bar with 'Home', 'Online First', 'Current Issue', 'All Issues', 'CHEST Collections', 'Guidelines', 'CHEST Meeting Abstracts', 'Podcasts', and 'For Authors'. The main content area features a large article titled 'May 2013; 143(5_suppl) Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines'. The article includes a 'Disclaimer', a 'Panel List', and a 'List of Reviewers'. A red box highlights the 'Panel List' section, which lists the names of the panel members. A red arrow points from the 'Links to Guidelines' section on the left to the 'Panel List' section on the right.



精选的肺癌相关的公开信息

The screenshot displays the Thomson Reuters Integrity website interface. At the top, the logo for Thomson Reuters Integrity is visible, along with the text "Disease Briefings". Below the logo, there are navigation tabs for "Knowledge Areas" and "Quick Search". The main content area is titled "Lung Cancer" and is divided into several sections:

- Facts about Lung Cancer**: A dropdown menu with options for "Diagnosis", "Prevention", "Treatment", "Targets for Therapeutic Intervention", "Latest Headlines", and "Glossary of Terms".
- Links**: A section with a red border around the "Links to Selected Publications" option. Other options include "Links to Related Websites" and "Links to Guidelines".
- Related Info**: A section with options for "Drugs & Biologics (290)" and "Literature (201)".
- Print Full Document**: A button with a printer icon.

The "Links to Selected Publications" section contains the following information:

Links to Selected Publications

- Breathing in America: Diseases, progress, and hope (American Thoracic Society, 2010)
<http://www.thoracic.org/education/breathing-in-america.pdf>
- Cancer facts & figures 2010 (American Cancer Society)
<http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/document/acspc-026238.pdf>
- Cancer facts & figures 2011 (American Cancer Society)
<http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011>
- Cancer facts & figures 2012 (American Cancer Society)
<http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/document/acspc-031941.pdf>
- Cancer facts & figures 2013 (American Cancer Society)
<http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/document/acspc-036845.pdf>
- ecancer (open access cancer journal from the European Institute of Oncology)
<http://ecancer.org/>
- Estimated prevalence and incidence of lung disease (American Lung Association, April 2013)
<http://www.lung.org/finding-cures/our-research/trend-reports/estimated-prevalence.pdf>
- Food, Nutrition and the Prevention of Cancer: A Global Perspective
<http://www.dietandcancerreport.org>
- Global Cancer Facts & Figures 2007 (American Cancer Society, 2007)
<http://www.cancer.org/acs/groups/content/@nho/documents/document/globalfactsandfigures2007rev2p.pdf>
- Lung cancer (PDQ®): Prevention
<http://www.cancer.gov/cancertopics/pdq/prevention/lung/HealthProfessional>
- Lung cancer (PDQ®): Screening
<http://www.cancer.gov/cancertopics/pdq/screening/lung/HealthProfessional>

提纲

- Thomson Reuters Integrity数据库简介
- Integrity解决如下问题
 - 动态监测新分子实体和新靶标
 - 快速概览特定领域的研发进展和布局
 - 选题立项评估药物品种的综合状况
 - 比较药理学活性进行结构式优化
 - 一站式概览疾病综述和主流药物
 - 设置专属Email跟踪获取更新内容
- Q &A

基于检索式的跟踪，跟踪符合条件的新记录

THOMSON REUTERS
IntegritySM Drugs & Biologics

Knowledge Areas Quick Search go Home Support/Help Query Manager / Alert Center Reports

342725 Records in Drugs & Biologics
319553 Records with chemical structure

The Starting Line
A selection of new molecular entities and targets ready to enter the R&D arena.

Pipeline on the Move
Milestones for drugs under active development.

Gateways to Development Status
Select a condition to generate a program status list for compounds launched or under active development for that condition.

Lookup

- ▶ AIDS
- ▶ Anesthesia
- ▶ Cancer
- ▶ Cardiovascular Disorders
- ▶ Congenital defects
- ▶ Critical care medicine
- ▶ Dermatological Disorders
- ▶ Diagnostics
- ▶ Disorders of Sexual

Advanced Search Session History Clear Form **Start**

Product Structure Search

Lead Compounds Under Active Development

Natural Source (Y/N) ▶ Y Index AND ▶

Condition ▶ "Cardiovascular Disorders" Index AND ▶

Metabolites (Y/N) ▶ Index AND ▶

Reference

Select Value ▶ Index AND ▶

Optional Value ▶ Index AND ▶

Optional Value ▶ Index AND ▶

Targets & Pathways

Select Value ▶ Index AND ▶

Optional Value ▶ Index AND ▶

Optional Value ▶ Index AND ▶

Patent

Select Value ▶ Index AND ▶

Optional Value ▶ Index AND ▶

Optional Value ▶ Index AND ▶

Records Retrieved

345 in Drugs & Biologics Search Results

Options

Drugs & Biologics Search Results

Query > Natural Source (Y/N) = y AND Condition = "Cardiovascular Disorders"

Entry Number	Highest Phase	Code Name	Generic Name
<input type="checkbox"/> 070266	Biological Testing	RES-1149-2	
<input type="checkbox"/> 070274	Launched	MPC-004	Colchicine
<input type="checkbox"/> 090168	Preclinical	BDPH NSC-325307	Butylidenephthalolide
<input type="checkbox"/> 090703	Preclinical	FF-0019 NSC-77037	Hanfangchin A Tetrandrine d-Tetrandrine
<input type="checkbox"/> 090892	Preclinical	GFA	Guan-Fu base A Guanfu base A
<input type="checkbox"/> 090958	Preclinical		Dehydroevodiar chloride
<input type="checkbox"/> 090962	Phase II	NSC 36413	Dauricine

Save Query - Windows Internet Explorer

https://integrity.thomson-pharma.com/integrity/xmlxsl/query

Save Query

To save your query, enter a Query Name and Description and click Save Query.

A daily, weekly or monthly e-mail alert can be set up to notify you when new records are obtained with this query.

To set up an Alert, enter a Query Name and Description, click the Optional e-mail alert down arrow to choose a daily, weekly or monthly alert frequency, and then click Save Query.

When new records are obtained by this query, you will receive notification by e-mail.

Query Name:

Description:

Optional e-mail alert:

Save Query

Organization
Ywa Hakko
ott
.Pharma
na-Aldrich
ei Medical
ege
ese Academy
medical
inces
ginator)
(en
iginator)
enia Hope
ional Cancer
titude
inghai
titude Materia
tica (SIMM)
iginator)
nese
University of
Hong Kong
(Originator)

Filter by Statistics

- Development Status
- Organization
- Major Therapeutic Groups
- Therapeutic Group
- Major Condition Groups
- Condition
 - Molecular Mechanisms
 - Cellular Mechanisms
- Major Product Categories
- Product Category
- Launch Year
- Therapeutic Impact and Organization (3D chart)
- Target
- Under Active Development / No Development Reported
- Condition and Phase (3D chart)
- Filter Only Lead Compound
- Natural Source Categories
- Natural Source Scientific Name
- Prescription/ Indication Type
- Administration Route

基于检索结果的跟踪，跟踪某些记录的最新变化

THOMSON REUTERS
IntegritySM Drugs & Biologics

Knowledge Areas Quick Search Home Support/Help Query Manager / Alert Center Reports

Records Retrieved 345 in Drugs & Biologics Search Results

Drugs & Biologics Search Results

Query > Natural Source (Y/N) = y AND Condition = "Cardiovascular Disorders"

Options

- Save Query
- Keep Me Posted
- Export Center
- Integrity Reports
- Full Records
- Product List with Structures
- Display Milestones
- Gateways to Product Development Status
- References
- Patents
- All Related Information via Quick Search
- Printer Friendly Format

Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Product Category	Therapeutic Group	Organization
<input checked="" type="checkbox"/> 070266	Biological Testing	RES-1149-2				Antineoplastic Antihypertension, Treatment of	Iowa Hakko
<input checked="" type="checkbox"/> 070274	Launched	MPC-004	Colchicine	Colcris Colstat		Antibiotics and Anticardiovascular Diseases (Not Specified)	Abbott Laboratories
<input checked="" type="checkbox"/> 090168	Preclinical	BDPH NSC-325307	Butylidenephthalide Ligusticum lactone			Angina pectoris, Treatment of Smooth Muscle Relaxants	Gamma-Aldrich
<input type="checkbox"/> 090703	Preclinical	FF-0019 NSC-77037	Hanfanchin A Tetrandrine d-Tetrandrine		Alkaloids	Antidiabetic Drugs Antimalarials Colorectal Cancer Therapy Hypertension, Treatment of Multidrug Resistance Modulators Oncolytic Drugs	Chinese Academy of Medical Sciences (Originator) Shengchen (Originator) Henia Hope International Cancer Institute
<input type="checkbox"/> 090892	Preclinical	GFA	Guan-Fu base A Guanfu base A			Antiarrhythmic Drugs	Shanghai Institute Materia Medica (SIMM) (Originator)

Filter by Statistics

- Development Status
- Organization
- Major Therapeutic Groups
- Therapeutic Group
- Major Condition Groups
- Condition
- Mechanistic Scope
 - Molecular Mechanisms
 - Cellular Mechanisms
- Major Product Categories
- Product Category
- Launch Year
- Therapeutic Impact and Organization (3D chart)
- Target
- Under Active Development / No Development Reported
- Condition and Phase (3D chart)
- Filter Only Lead Compound
- Natural Source Categories
- Natural Source Scientific Name

Save Query - Windows Internet Explorer

https://integrity.thomson-pharma.com/integrity/xmlxsl/record_updates_ui_pkg.ne

Use the Keep Me Posted utility of Integrity to be advised by e-mail when changes occur to a set of records.

Enter an Alert Name and Description and select the field or fields to be monitored for change. Optional e-mail alert down arrow to choose a daily, weekly or monthly alert frequency, and Create Alert.

When a change occurs in a selected field for any record in the set, you will receive notification by e-mail.

Alert Name

Description

Changes monitored

<input checked="" type="checkbox"/> Updated Highest Phase Field	<input checked="" type="checkbox"/> New / Updated Structure
<input type="checkbox"/> Updated "Under Active Development" Flag	<input type="checkbox"/> New Chemical Name
<input type="checkbox"/> New CAS Registry Number	<input type="checkbox"/> New Product Name
<input checked="" type="checkbox"/> New Mechanism of Action	<input type="checkbox"/> New Therapeutic Group
<input checked="" type="checkbox"/> New Condition	<input type="checkbox"/> New Organization
<input type="checkbox"/> Development Status Table Newly Available	<input type="checkbox"/> Milestone History Newly Available
<input checked="" type="checkbox"/> New Milestone	<input type="checkbox"/> New Related Patent Family
<input type="checkbox"/> New Related Reference	

Optional e-mail alert

该药物的最新研发状态的改变；新的治疗领域的发现；新的研究机构的介入；新的专利的产生等等

特定报告中设置跟踪：Options-Keep me posted

Records Retrieved 1 in Dr

Drugs & Biologics Search Results

Entry Number 162288 **UPDA**

CAS Registry No. 124750-99-8
114798-26-4 (

Molecular Formula C22H22ClN6

Molecular Weight 461.001

Highest Phase Launched - 19

Physical Properties White crystals

Under Active Development

Chemical Name/Description
5-[4'-(2-Butyl-4-chloro-5-(hydroxymethyl)-2-Butyl-4-chloro-5-(hydroxymethyl)-

Standard InChI
1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)14H2,1H3;/q-1;+1

Standard InChIKey
OXCMYAYHXIHQQA-UHFFFAOYSA-N

Code Name DuP-753 **Generic Name** Losartan potassium **Brand Name** Covance **SALES**

Filter by Statistics

- Development Status
- Organization
- Major Therapeutic Groups
- Therapeutic Group
- Major Condition Groups
- Condition
 - Mechanistic Scope
 - Molecular Mechanisms
 - Cellular Mechanisms
- Major Product Categories
- Product Category
- Launch Year
- Therapeutic Impact and Organization (3D chart)
- Target
- Under Active Development / No Development Reported
- Condition and Phase (3D chart)
- Filter Only Lead Compounds
- Natural Source Categories

Records Retrieved 345 in Drugs & Biologics Search Results

Options

Query Manager - Windows Internet Explorer

https://integrity.thomson-pharma.com/integrity/xmlxsl/alert_center_ui_pkg.alertCenterForm

THOMSON REUTERS
IntegritySM Query Manager/Alert Center

Saved Queries

Keep Me Posted

Controlled Vocabulary

Session History

Filter

VIEW ALL

Alert Set	Query Name	Description	Knowledge Area	Last Performed	
<input type="radio"/>	Alzheimer	all	Drugs & Biologics	Sep 27, 2009	options
<input type="radio"/>	2-Chlorobenzonitrile	Lianhe Chemical	Organic Synthesis	May 07, 2009	options
<input type="radio"/>	0-dichlorobenzonitrile		Drugs & Biologics	Jun 05, 2009	options
<input type="radio"/>	Gefitinib(Structure search)		Drugs & Biologics	Jun 09, 2009	options
<input type="radio"/>	Structure1		Organic Synthesis	Jun 19, 2009	options
<input type="radio"/>	Structure 2		Organic Synthesis	Jun 19, 2009	options
<input type="radio"/>	Clinical Search	Condition = "Cardiovascular Disorders" AND Natural Source (Y/N) = y	Clinical Studies	Mar 20, 2011	options
<input type="radio"/>	Drug Substances patents	Subject Matters = "Drug Substances" AND Phase = "Launched"	Patents	Mar 20, 2011	options
<input type="radio"/>	Pharmacology Search	Include Literature Results = Y AND Include Patent Results = Y AND Experimental Activity = "1-Deoxy-D-Xylulose-5-Phosphat	Experimental Pharmacology	Mar 20, 2011	options
<input checked="" type="radio"/>	EGFR drugs	Name = "EGFR variant 1" or "EGFR variant c" or "EGFR-RS" or "EGFR2" or "EGFR3" or "EGFR4" Mar 20, 2011 1342	Drugs & Biologics	Mar 20, 2011	Execute Delete Edit View Details

Query Manager - Windows Internet Explorer

https://integrity.thomson-pharma.com/integrity/xmlxsl/alert_center_ui_pkg.alertCenterForm?p_pestania=3&p_page=1

THOMSON REUTERS
IntegritySM Query Manager/Alert

最近24小时内的检索历史

[Saved Queries](#)
[Keep Me Posted](#)
[Controlled Vocabulary](#)
[Session History](#)

1 2 3

Knowledge Area	Query Conditions	Last Performed	Results	
Drugs & Biologics	Natural Source (Y/N) = y AND Condition = "Cardiovascular Disorders"	Mar 20, 2011	345	options ▾
Drugs & Biologics	Structure Search =	Mar 20, 2011	1693	options ▾
Quick Search	304079	Mar 20, 2011	1	options ▾
Quick Search	I036	Mar 20, 2011	533	options ▾
Quick Search	I036	Mar 20, 2011	533	options ▾
Patents	Subject Matters = "Drug Substances" AND Phase = "Launched"	Mar 20, 2011	885	options ▾
Quick Search	EGFR	Mar 20, 2011	8733	options ▾
Drugs & Biologics	Name = "EGFR variant 1" or "EGFR variant c" or "EGFR-RS" or "EGFR2" or "EGFR3" or "EGFR4"	Mar 20, 2011	1342	options ▾
Targets & Pathways	Condition = "Cardiovascular Disorders"	Mar 20, 2011	879	options ▾
Quick Search	caco-2/efflux	Mar 20, 2011	2	options ▾

1 2 3

完成 Internet 100%

提纲

- Thomson Reuters Integrity数据库简介
- Integrity解决如下问题
 - 动态监测新分子实体和新靶标
 - 快速概览特定领域的研发进展和布局
 - 选题立项评估药物品种的综合状况
 - 比较药理学活性进行结构式优化
 - 一站式概览疾病综述和主流药物
 - 设置专属Email跟踪获取更新内容
- Q &A

制药前沿博客

来源于汤森路透生命科学专家的行业见解、评论和前沿动态

<http://lsconnect.thomsonreuters.com>

LIFE SCIENCES CONNECT



THOMSON REUTERS

The Price of Doing Business – How Will GDUFA Change the API Industry



23 SEP 2013
Michael Glessner

Michael Glessner, Pharmaceutical Research Analyst at Thomson Reuters, discusses how the introduction of the Generic Drug User Fee Act (GDUFA) will influence the API industry and how long these changes are likely to take to come into effect.

One-Time Fee

On Oct. 1, 2012, the U. S. Food and Drug Administration (FDA) implemented the long-discussed GDUFA, authorizing the agency to collect fees from any manufacturers worldwide who wish for their active pharmaceutical ingredients (APIs) to be eligible for use in generic drugs sold in the U. S.

[READ MORE ▶](#)

SHARE



USEFUL RESOURCES

- [Subscribe to Blog](#)
- [Sign up to RSS Feed](#)
- [Latest News](#)
- [Find us on Twitter](#)
- [Join us on LinkedIn](#)

TOPICS

- [Business Development](#)
- [Clinical Development](#)
- [Information Intelligence](#)
- [Intellectual Property](#)
- [Product Portfolio Development](#)
- [Regulatory Affairs](#)
- [Research and Development](#)
- [Sourcing and Manufacturing](#)

TAGS

alzheimers ANDA api **AstraZeneca** Aveo
Bayer biomarkers BioPharma biosimilars
BioWorld **cancer** celgene clinical
development clinical phase **clinical trials**
Castalia



THOMSON
汤森路透

更多增值服务

- 关注“汤森路透生命科学与制药”官方微信
扫描二维码 或 搜索“汤森路透生命科学与制药”



- 下载行业报告：

<http://ip-science.thomsonreuters.com.cn/lscn/reports-whitepapers/index.shtml>




《仿制药发展动态》




《药业新观察》



《临床试验进展》




《化学前沿》



《焦点》

- 数据库使用培训课程：

<http://ip-science.thomsonreuters.com.cn/lscn/training/index.shtml>



谢谢!

张慧

产品与方案解决专家，生命科学事业部

汤森路透

座机: +86 10 5760 1306

手机: +86 13770529090

h.zhang@thomsonreuters.com

